WO2018030874A1 - 조작된 면역조절요소 및 이에 의해 변형된 면역 활성 - Google Patents
조작된 면역조절요소 및 이에 의해 변형된 면역 활성 Download PDFInfo
- Publication number
- WO2018030874A1 WO2018030874A1 PCT/KR2017/008835 KR2017008835W WO2018030874A1 WO 2018030874 A1 WO2018030874 A1 WO 2018030874A1 KR 2017008835 W KR2017008835 W KR 2017008835W WO 2018030874 A1 WO2018030874 A1 WO 2018030874A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- domain
- sequence
- gene
- complementary
- Prior art date
Links
- 230000004957 immunoregulator effect Effects 0.000 title claims abstract description 62
- 230000036039 immunity Effects 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 501
- 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 claims abstract description 41
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims abstract description 41
- 102100023227 E3 SUMO-protein ligase EGR2 Human genes 0.000 claims abstract description 36
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims abstract description 34
- 229940045513 CTLA4 antagonist Drugs 0.000 claims abstract description 31
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims abstract description 31
- 101001025967 Homo sapiens Lysine-specific demethylase 6A Proteins 0.000 claims abstract description 25
- 102100037462 Lysine-specific demethylase 6A Human genes 0.000 claims abstract description 25
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims abstract description 10
- 101001049692 Homo sapiens E3 SUMO-protein ligase EGR2 Proteins 0.000 claims abstract 10
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims abstract 9
- 101000761581 Homo sapiens Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B delta isoform Proteins 0.000 claims abstract 9
- 102100024927 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B delta isoform Human genes 0.000 claims abstract 9
- 230000000295 complement effect Effects 0.000 claims description 493
- 150000007523 nucleic acids Chemical group 0.000 claims description 359
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 305
- 210000002865 immune cell Anatomy 0.000 claims description 294
- 102000039446 nucleic acids Human genes 0.000 claims description 244
- 108020004707 nucleic acids Proteins 0.000 claims description 244
- 108091033409 CRISPR Proteins 0.000 claims description 236
- 102000004169 proteins and genes Human genes 0.000 claims description 196
- 210000004027 cell Anatomy 0.000 claims description 136
- 230000004048 modification Effects 0.000 claims description 136
- 238000012986 modification Methods 0.000 claims description 124
- 239000002773 nucleotide Substances 0.000 claims description 97
- 125000003729 nucleotide group Chemical group 0.000 claims description 97
- 230000000694 effects Effects 0.000 claims description 94
- 230000027455 binding Effects 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 54
- 241000589875 Campylobacter jejuni Species 0.000 claims description 42
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 42
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 37
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 31
- 210000000822 natural killer cell Anatomy 0.000 claims description 27
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 25
- 238000007385 chemical modification Methods 0.000 claims description 25
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 24
- 108091008874 T cell receptors Proteins 0.000 claims description 23
- 101150064015 FAS gene Proteins 0.000 claims description 22
- 241000191967 Staphylococcus aureus Species 0.000 claims description 20
- 238000010353 genetic engineering Methods 0.000 claims description 20
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 17
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 claims description 15
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 claims description 15
- 108020001507 fusion proteins Proteins 0.000 claims description 15
- 102000037865 fusion proteins Human genes 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 14
- 101150050688 DGKA gene Proteins 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 12
- 238000003780 insertion Methods 0.000 claims description 12
- 230000037431 insertion Effects 0.000 claims description 12
- 101150059401 EGR2 gene Proteins 0.000 claims description 11
- 238000012217 deletion Methods 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 11
- 101100073568 Homo sapiens KDM6A gene Proteins 0.000 claims description 9
- 101150105871 KDM6A gene Proteins 0.000 claims description 9
- 101150109113 ppp2r2d gene Proteins 0.000 claims description 8
- 241000588650 Neisseria meningitidis Species 0.000 claims description 7
- 230000002068 genetic effect Effects 0.000 claims description 7
- 239000013603 viral vector Substances 0.000 claims description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 238000004520 electroporation Methods 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 238000001814 protein method Methods 0.000 claims description 2
- 230000007398 protein translocation Effects 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 108700005075 Regulator Genes Proteins 0.000 claims 1
- 238000012224 gene deletion Methods 0.000 claims 1
- 230000006870 function Effects 0.000 abstract description 90
- 230000014509 gene expression Effects 0.000 abstract description 38
- 210000000987 immune system Anatomy 0.000 abstract description 23
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 abstract description 16
- 230000001900 immune effect Effects 0.000 abstract description 15
- 230000001976 improved effect Effects 0.000 abstract description 14
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 abstract description 13
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 abstract description 13
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 abstract description 13
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 abstract description 13
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 abstract description 13
- 235000018102 proteins Nutrition 0.000 description 176
- 108020005004 Guide RNA Proteins 0.000 description 134
- 239000000427 antigen Substances 0.000 description 120
- 108091007433 antigens Proteins 0.000 description 120
- 102000036639 antigens Human genes 0.000 description 120
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 description 99
- 235000001014 amino acid Nutrition 0.000 description 84
- 229940024606 amino acid Drugs 0.000 description 83
- 230000028993 immune response Effects 0.000 description 81
- 150000001413 amino acids Chemical class 0.000 description 79
- 102000005962 receptors Human genes 0.000 description 66
- 108020003175 receptors Proteins 0.000 description 66
- 230000001105 regulatory effect Effects 0.000 description 62
- 102000004190 Enzymes Human genes 0.000 description 61
- 108090000790 Enzymes Proteins 0.000 description 61
- 108091000080 Phosphotransferase Proteins 0.000 description 60
- 102000020233 phosphotransferase Human genes 0.000 description 60
- 241000894007 species Species 0.000 description 54
- 108090000765 processed proteins & peptides Proteins 0.000 description 45
- 108010031480 Artificial Receptors Proteins 0.000 description 44
- 101710163270 Nuclease Proteins 0.000 description 43
- 108020004414 DNA Proteins 0.000 description 33
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 33
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 31
- 230000035897 transcription Effects 0.000 description 30
- 238000013518 transcription Methods 0.000 description 30
- -1 PPP2R2D Proteins 0.000 description 28
- 238000010354 CRISPR gene editing Methods 0.000 description 27
- 108010051748 Early Growth Response Protein 2 Proteins 0.000 description 26
- 206010028980 Neoplasm Diseases 0.000 description 26
- 230000002519 immonomodulatory effect Effects 0.000 description 26
- 102000004196 processed proteins & peptides Human genes 0.000 description 26
- 102000004127 Cytokines Human genes 0.000 description 24
- 108090000695 Cytokines Proteins 0.000 description 24
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 23
- 229920001184 polypeptide Polymers 0.000 description 22
- 230000028327 secretion Effects 0.000 description 22
- 101710192015 Diacylglycerol kinase zeta Proteins 0.000 description 19
- 108010076504 Protein Sorting Signals Proteins 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 102100030220 Diacylglycerol kinase zeta Human genes 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 18
- 230000030833 cell death Effects 0.000 description 18
- 108010062677 Diacylglycerol Kinase Proteins 0.000 description 17
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 17
- 235000004279 alanine Nutrition 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 238000003776 cleavage reaction Methods 0.000 description 16
- 230000007017 scission Effects 0.000 description 16
- 125000003275 alpha amino acid group Chemical group 0.000 description 15
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 15
- 230000010261 cell growth Effects 0.000 description 14
- 230000006780 non-homologous end joining Effects 0.000 description 14
- 230000036961 partial effect Effects 0.000 description 14
- 102100037850 Interferon gamma Human genes 0.000 description 13
- 108010074328 Interferon-gamma Proteins 0.000 description 13
- 210000000349 chromosome Anatomy 0.000 description 13
- 230000004069 differentiation Effects 0.000 description 13
- 238000012239 gene modification Methods 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 108091027544 Subgenomic mRNA Proteins 0.000 description 12
- 108010047933 Tumor Necrosis Factor alpha-Induced Protein 3 Proteins 0.000 description 12
- 102100024596 Tumor necrosis factor alpha-induced protein 3 Human genes 0.000 description 12
- 210000004405 cytokine-induced killer cell Anatomy 0.000 description 12
- 102000011107 Diacylglycerol Kinase Human genes 0.000 description 11
- 102100022735 Diacylglycerol kinase alpha Human genes 0.000 description 11
- 101710181033 Diacylglycerol kinase alpha Proteins 0.000 description 11
- 241000588653 Neisseria Species 0.000 description 11
- 230000021736 acetylation Effects 0.000 description 11
- 238000006640 acetylation reaction Methods 0.000 description 11
- 235000003704 aspartic acid Nutrition 0.000 description 11
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 11
- 239000003630 growth substance Substances 0.000 description 11
- 230000011987 methylation Effects 0.000 description 11
- 238000007069 methylation reaction Methods 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 11
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 230000014616 translation Effects 0.000 description 11
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 10
- 108091028113 Trans-activating crRNA Proteins 0.000 description 10
- 230000033228 biological regulation Effects 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 201000009906 Meningitis Diseases 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 108020004635 Complementary DNA Proteins 0.000 description 8
- 101150057529 Dgkz gene Proteins 0.000 description 8
- 241000904817 Lachnospiraceae bacterium Species 0.000 description 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
- 101150012475 TET2 gene Proteins 0.000 description 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 8
- 239000004473 Threonine Substances 0.000 description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000002147 killing effect Effects 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000008439 repair process Effects 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 7
- 102000007474 Multiprotein Complexes Human genes 0.000 description 7
- 108010085220 Multiprotein Complexes Proteins 0.000 description 7
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 7
- 238000002659 cell therapy Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 102100037931 Harmonin Human genes 0.000 description 6
- 101000805947 Homo sapiens Harmonin Proteins 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000003071 memory t lymphocyte Anatomy 0.000 description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 230000004952 protein activity Effects 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- 239000004474 valine Substances 0.000 description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 5
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 101100166147 Streptococcus thermophilus cas9 gene Proteins 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 230000003915 cell function Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 241000093740 Acidaminococcus sp. Species 0.000 description 4
- 241000605902 Butyrivibrio Species 0.000 description 4
- 241001040999 Candidatus Methanoplasma termitum Species 0.000 description 4
- 241000243205 Candidatus Parcubacteria Species 0.000 description 4
- 241000223282 Candidatus Peregrinibacteria Species 0.000 description 4
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 241000589599 Francisella tularensis subsp. novicida Species 0.000 description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 4
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 4
- 101710204288 Melanoma-associated antigen 3 Proteins 0.000 description 4
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 4
- 108060004795 Methyltransferase Proteins 0.000 description 4
- 241000542065 Moraxella bovoculi Species 0.000 description 4
- 102000002488 Nucleoplasmin Human genes 0.000 description 4
- 241000878522 Porphyromonas crevioricanis Species 0.000 description 4
- 241001135219 Prevotella disiens Species 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 102100036234 Synaptonemal complex protein 1 Human genes 0.000 description 4
- 102100036407 Thioredoxin Human genes 0.000 description 4
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 4
- 241001531273 [Eubacterium] eligens Species 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 108091005948 blue fluorescent proteins Proteins 0.000 description 4
- 230000006727 cell loss Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 108010082025 cyan fluorescent protein Proteins 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000003197 gene knockdown Methods 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 230000005931 immune cell recruitment Effects 0.000 description 4
- 102000035118 modified proteins Human genes 0.000 description 4
- 108091005573 modified proteins Proteins 0.000 description 4
- PUPNJSIFIXXJCH-UHFFFAOYSA-N n-(4-hydroxyphenyl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound C1=CC(O)=CC=C1NC(=O)CN1S(=O)(=O)C2=CC=CC=C2C1=O PUPNJSIFIXXJCH-UHFFFAOYSA-N 0.000 description 4
- 108060005597 nucleoplasmin Proteins 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 108060008226 thioredoxin Proteins 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 102100028559 Death domain-associated protein 6 Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 3
- 241001112693 Lachnospiraceae Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 101100166144 Staphylococcus aureus cas9 gene Proteins 0.000 description 3
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 3
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 3
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 101150063845 dgk gene Proteins 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000004986 primary T-cell Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 2
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 102100032306 Aurora kinase B Human genes 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 241000605059 Bacteroidetes Species 0.000 description 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 102100033680 Bombesin receptor-activated protein C6orf89 Human genes 0.000 description 2
- 108700012439 CA9 Proteins 0.000 description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 2
- 102100024263 CD160 antigen Human genes 0.000 description 2
- 108010065524 CD52 Antigen Proteins 0.000 description 2
- 210000005236 CD8+ effector T cell Anatomy 0.000 description 2
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 2
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 102100027668 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 Human genes 0.000 description 2
- 101710134395 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 Proteins 0.000 description 2
- 102100031437 Cell cycle checkpoint protein RAD1 Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 102100032952 Condensin complex subunit 3 Human genes 0.000 description 2
- 102100025571 Cutaneous T-cell lymphoma-associated antigen 1 Human genes 0.000 description 2
- 102100033934 DNA repair protein RAD51 homolog 2 Human genes 0.000 description 2
- 102100033587 DNA topoisomerase 2-alpha Human genes 0.000 description 2
- 102100033589 DNA topoisomerase 2-beta Human genes 0.000 description 2
- 101710091772 Death domain-associated protein 6 Proteins 0.000 description 2
- 108010033174 Deoxycytidine kinase Proteins 0.000 description 2
- 108010058222 Deoxyguanosine kinase Proteins 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 102100022733 Diacylglycerol kinase epsilon Human genes 0.000 description 2
- 102100035273 E3 ubiquitin-protein ligase CBL-B Human genes 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 102100031812 Fibulin-1 Human genes 0.000 description 2
- 101710170731 Fibulin-1 Proteins 0.000 description 2
- 102100020714 Fragile X mental retardation 1 neighbor protein Human genes 0.000 description 2
- 101710121810 Galectin-9 Proteins 0.000 description 2
- 102100031351 Galectin-9 Human genes 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102100028963 Guanylate cyclase soluble subunit beta-2 Human genes 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 2
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 2
- 102100022650 Homeobox protein Hox-A7 Human genes 0.000 description 2
- 102100025056 Homeobox protein Hox-B6 Human genes 0.000 description 2
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 101000984746 Homo sapiens BRCA1-associated protein Proteins 0.000 description 2
- 101000944524 Homo sapiens Bombesin receptor-activated protein C6orf89 Proteins 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 2
- 101001130384 Homo sapiens Cell cycle checkpoint protein RAD1 Proteins 0.000 description 2
- 101000942622 Homo sapiens Condensin complex subunit 3 Proteins 0.000 description 2
- 101000856239 Homo sapiens Cutaneous T-cell lymphoma-associated antigen 1 Proteins 0.000 description 2
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 2
- 101001132307 Homo sapiens DNA repair protein RAD51 homolog 2 Proteins 0.000 description 2
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 description 2
- 101000932499 Homo sapiens Fragile X mental retardation 1 neighbor protein Proteins 0.000 description 2
- 101001059095 Homo sapiens Guanylate cyclase soluble subunit beta-2 Proteins 0.000 description 2
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 description 2
- 101001045116 Homo sapiens Homeobox protein Hox-A7 Proteins 0.000 description 2
- 101001077542 Homo sapiens Homeobox protein Hox-B6 Proteins 0.000 description 2
- 101000911772 Homo sapiens Hsc70-interacting protein Proteins 0.000 description 2
- 101100452137 Homo sapiens IGF2BP3 gene Proteins 0.000 description 2
- 101000945331 Homo sapiens Killer cell immunoglobulin-like receptor 2DL4 Proteins 0.000 description 2
- 101001008951 Homo sapiens Kinesin-like protein KIF15 Proteins 0.000 description 2
- 101001054842 Homo sapiens Leucine zipper protein 4 Proteins 0.000 description 2
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 description 2
- 101100519206 Homo sapiens PDCD1 gene Proteins 0.000 description 2
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 2
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 2
- 101000880771 Homo sapiens Protein SSX3 Proteins 0.000 description 2
- 101000880774 Homo sapiens Protein SSX4 Proteins 0.000 description 2
- 101000880775 Homo sapiens Protein SSX5 Proteins 0.000 description 2
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 2
- 101000743264 Homo sapiens RNA-binding protein 6 Proteins 0.000 description 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
- 101000756066 Homo sapiens Serine/threonine-protein kinase RIO1 Proteins 0.000 description 2
- 101000632529 Homo sapiens Shugoshin 1 Proteins 0.000 description 2
- 101000784541 Homo sapiens Zinc finger and SCAN domain-containing protein 21 Proteins 0.000 description 2
- 101000856240 Homo sapiens cTAGE family member 2 Proteins 0.000 description 2
- 102100027037 Hsc70-interacting protein Human genes 0.000 description 2
- 102100027735 Hyaluronan mediated motility receptor Human genes 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100037920 Insulin-like growth factor 2 mRNA-binding protein 3 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102100033633 Killer cell immunoglobulin-like receptor 2DL4 Human genes 0.000 description 2
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 description 2
- 102100027630 Kinesin-like protein KIF15 Human genes 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 101710128836 Large T antigen Proteins 0.000 description 2
- 241001148627 Leptospira inadai Species 0.000 description 2
- 102100026910 Leucine zipper protein 4 Human genes 0.000 description 2
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 2
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 102100033247 Lysine-specific demethylase 5B Human genes 0.000 description 2
- 101710105712 Lysine-specific demethylase 5B Proteins 0.000 description 2
- 108010010995 MART-1 Antigen Proteins 0.000 description 2
- 102100025096 Mesothelin Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101000753280 Mus musculus Angiopoietin-1 receptor Proteins 0.000 description 2
- 101100078999 Mus musculus Mx1 gene Proteins 0.000 description 2
- 201000004458 Myoma Diseases 0.000 description 2
- 102100026949 Opioid growth factor receptor Human genes 0.000 description 2
- 101710130302 Opioid growth factor receptor Proteins 0.000 description 2
- 101150087384 PDCD1 gene Proteins 0.000 description 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 241001135241 Porphyromonas macacae Species 0.000 description 2
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102100037686 Protein SSX2 Human genes 0.000 description 2
- 102100037726 Protein SSX3 Human genes 0.000 description 2
- 102100037727 Protein SSX4 Human genes 0.000 description 2
- 102100037723 Protein SSX5 Human genes 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 230000007022 RNA scission Effects 0.000 description 2
- 102100038150 RNA-binding protein 6 Human genes 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 102100029627 Ribosomal RNA processing protein 1 homolog A Human genes 0.000 description 2
- 101710166144 Ribosomal RNA processing protein 1 homolog A Proteins 0.000 description 2
- 102100022261 Serine/threonine-protein kinase RIO1 Human genes 0.000 description 2
- 102100028402 Shugoshin 1 Human genes 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 101710143177 Synaptonemal complex protein 1 Proteins 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 102100039094 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 2
- 102100020917 Zinc finger and SCAN domain-containing protein 21 Human genes 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 102000009899 alpha Karyopherins Human genes 0.000 description 2
- 108010077099 alpha Karyopherins Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108010021843 fluorescent protein 583 Proteins 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 108010003425 hyaluronan-mediated motility receptor Proteins 0.000 description 2
- 102000027596 immune receptors Human genes 0.000 description 2
- 108091008915 immune receptors Proteins 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 108700032552 influenza virus INS1 Proteins 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 230000030147 nuclear export Effects 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000009711 regulatory function Effects 0.000 description 2
- 108020003113 steroid hormone receptors Proteins 0.000 description 2
- 102000005969 steroid hormone receptors Human genes 0.000 description 2
- 101150003509 tag gene Proteins 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 1
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 description 1
- 241001156739 Actinobacteria <phylum> Species 0.000 description 1
- 241000186045 Actinomyces naeslundii Species 0.000 description 1
- 241001147780 Alicyclobacillus Species 0.000 description 1
- 102100033805 Alpha-protein kinase 1 Human genes 0.000 description 1
- 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 241001142141 Aquificae <phylum> Species 0.000 description 1
- 241000589941 Azospirillum Species 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100026549 Caspase-10 Human genes 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100038918 Caspase-6 Human genes 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- 241001185363 Chlamydiae Species 0.000 description 1
- 241001142109 Chloroflexi Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102100026846 Cytidine deaminase Human genes 0.000 description 1
- 108010031325 Cytidine deaminase Proteins 0.000 description 1
- 102000013816 Cytotoxic T-lymphocyte antigen 4 Human genes 0.000 description 1
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 description 1
- 101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 description 1
- 241000936939 Desulfonatronum Species 0.000 description 1
- 241000605716 Desulfovibrio Species 0.000 description 1
- 102100034185 E3 ubiquitin-protein ligase RLIM Human genes 0.000 description 1
- 101150000195 EGR3 gene Proteins 0.000 description 1
- 102100021717 Early growth response protein 3 Human genes 0.000 description 1
- 241001260322 Elusimicrobia <phylum> Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 101000809594 Escherichia coli (strain K12) Shikimate kinase 1 Proteins 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 102100022466 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 description 1
- 108050000946 Eukaryotic translation initiation factor 4E-binding protein 1 Proteins 0.000 description 1
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 1
- 241000923108 Fibrobacteres Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241001453172 Fusobacteria Species 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 241000032681 Gluconacetobacter Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102100040754 Guanylate cyclase soluble subunit alpha-1 Human genes 0.000 description 1
- 102100040735 Guanylate cyclase soluble subunit alpha-2 Human genes 0.000 description 1
- 108050008753 HNH endonucleases Proteins 0.000 description 1
- 102000000310 HNH endonucleases Human genes 0.000 description 1
- 101150046249 Havcr2 gene Proteins 0.000 description 1
- 241001430278 Helcococcus Species 0.000 description 1
- 102100028008 Heme oxygenase 2 Human genes 0.000 description 1
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 102100035081 Homeobox protein TGIF1 Human genes 0.000 description 1
- 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000903742 Homo sapiens Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 description 1
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000983518 Homo sapiens Caspase-10 Proteins 0.000 description 1
- 101000741087 Homo sapiens Caspase-6 Proteins 0.000 description 1
- 101000741014 Homo sapiens Caspase-7 Proteins 0.000 description 1
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 description 1
- 101100443104 Homo sapiens DGKA gene Proteins 0.000 description 1
- 101000915428 Homo sapiens Death domain-associated protein 6 Proteins 0.000 description 1
- 101000864576 Homo sapiens Diacylglycerol kinase zeta Proteins 0.000 description 1
- 101000711924 Homo sapiens E3 ubiquitin-protein ligase RLIM Proteins 0.000 description 1
- 101000896450 Homo sapiens Early growth response protein 3 Proteins 0.000 description 1
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101001038755 Homo sapiens Guanylate cyclase soluble subunit alpha-1 Proteins 0.000 description 1
- 101001038749 Homo sapiens Guanylate cyclase soluble subunit alpha-2 Proteins 0.000 description 1
- 101001079615 Homo sapiens Heme oxygenase 2 Proteins 0.000 description 1
- 101000596925 Homo sapiens Homeobox protein TGIF1 Proteins 0.000 description 1
- 101001083151 Homo sapiens Interleukin-10 receptor subunit alpha Proteins 0.000 description 1
- 101001003149 Homo sapiens Interleukin-10 receptor subunit beta Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 description 1
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001091194 Homo sapiens Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 description 1
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 1
- 101001068027 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Proteins 0.000 description 1
- 101001068019 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Proteins 0.000 description 1
- 101000836954 Homo sapiens Sialic acid-binding Ig-like lectin 10 Proteins 0.000 description 1
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 description 1
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 description 1
- 101000688930 Homo sapiens Signaling threshold-regulating transmembrane adapter 1 Proteins 0.000 description 1
- 101000863692 Homo sapiens Ski oncogene Proteins 0.000 description 1
- 101000688996 Homo sapiens Ski-like protein Proteins 0.000 description 1
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 description 1
- 101001135589 Homo sapiens Tyrosine-protein phosphatase non-receptor type 22 Proteins 0.000 description 1
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102100030236 Interleukin-10 receptor subunit alpha Human genes 0.000 description 1
- 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101710131918 Killer cell lectin-like receptor subfamily B member 1A Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241001453171 Leptotrichia Species 0.000 description 1
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 241000135938 Nitratifractor Species 0.000 description 1
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 description 1
- 241001386753 Parvibaculum Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100020847 Protein FosB Human genes 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 108091008680 RAR-related orphan receptors Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241000605947 Roseburia Species 0.000 description 1
- 102100034464 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Human genes 0.000 description 1
- 102100034470 Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Human genes 0.000 description 1
- 102100027164 Sialic acid-binding Ig-like lectin 10 Human genes 0.000 description 1
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 description 1
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 description 1
- 102100024453 Signaling threshold-regulating transmembrane adapter 1 Human genes 0.000 description 1
- 102100029969 Ski oncogene Human genes 0.000 description 1
- 102100024451 Ski-like protein Human genes 0.000 description 1
- 241000949716 Sphaerochaeta Species 0.000 description 1
- 241001180364 Spirochaetes Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 101000987219 Sus scrofa Pregnancy-associated glycoprotein 1 Proteins 0.000 description 1
- 101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 108091007178 TNFRSF10A Proteins 0.000 description 1
- 101150048713 Tnfaip3 gene Proteins 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 description 1
- 102100033138 Tyrosine-protein phosphatase non-receptor type 22 Human genes 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000043321 human CTLA4 Human genes 0.000 description 1
- 102000053578 human DGKZ Human genes 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 102000058153 human TET2 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000017730 intein-mediated protein splicing Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000000819 phase cycle Methods 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000006411 tonic activation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464462—Kinases, e.g. Raf or Src
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention is directed to artificially engineered immune systems with improved immune effects. More specifically, it relates to an artificially modified immune system, including artificially engineered immunoregulatory elements and cells comprising the same.
- Cell therapy is a medicine that induces therapeutic effects such as regeneration by using living cells to restore damaged or diseased cells, tissues, and individuals. Refers to medicines manufactured by chemical and biological methods.
- immunomodulatory cell therapy drugs are drugs used for the purpose of treating diseases by regulating the immune response in the body by using immune cells such as dendritic cells, natural killer cells, and T cells.
- immunomodulatory cell therapies are mainly developed as an indication for cancer treatment, and by directly injecting immune cells to patients to activate immune function, thereby obtaining a therapeutic effect, surgical therapy, chemotherapy or radiation therapy used in conventional cancer treatment. It has a different therapeutic mechanism and efficacy, and is expected to occupy a major part of bio-drug in the future.
- the immunomodulatory cell therapeutics have different physical and chemical characteristics of the substances introduced into the cells according to the type, and when the foreign genes are introduced into the immune cells as viral vectors, they have both characteristics of cell therapy and gene therapy.
- the immunomodulatory cell therapeutic agent activates various immune cells such as PBMC (Pipheral blood mononuclear cell), T cells, NK cells isolated from the patient through apheresis, and activates them with various antibodies and cytokines, and then multiplies them in vitro. It is injected into the patient, or by injecting the immune cells into which the gene such as TCR (T-Cell Receptor) or CAR (Chimeric Antigen Receptor) is introduced.
- PBMC Peripheral blood mononuclear cell
- T cells T cells
- NK cells isolated from the patient through apheresis
- Adoptive immunotherapy involving the delivery of autologous antigen-specific immune cells (eg T cells) produced ex vivo may be used to treat various immune disorders as well as cancer. It could be a promising strategy.
- autologous antigen-specific immune cells eg T cells
- an immune cell therapy agent can be used in various ways as an anti-cancer function as well as an autoimmune inhibitor, and thus, an immune cell therapy agent can be used for various indications by controlling an immune response. Therefore, there is a great demand for improving and developing the therapeutic efficacy of engineered immune cells used in adoptive immunotherapy.
- the present invention seeks to provide, in one embodiment, an artificially engineered immune system with improved immune effects.
- the present invention provides an artificially engineered immunomodulatory element and a cell comprising the same.
- the present invention seeks to provide a method of modifying (eg, enhancing or inhibiting) the function of immune cells.
- the present invention seeks to provide a therapeutic and / or prophylactic use of a disease associated with abnormal immune function, including an immunomodulatory element and / or immune cells with altered immune function.
- the present invention provides an anticancer function through enhancement of proliferation, survival, cytotoxicity, cell infiltration, and cytokine-release of immune cells. do.
- an immunomodulatory gene such as artificially engineered PD-1, CTLA-4, A20, DGK ⁇ , DGK ⁇ , FAS, EGR2, PPP2R2D, PSGL-1, KDM6A, TET2 and / or expression products thereof To provide.
- the present invention provides a composition for calibrating immune cell genome comprising a guide nucleic acid-editor protein complex applicable to the regulation of immunoregulatory gene activity and a method of using the same.
- the present invention can be used for the manipulation of immunomodulatory genes such as artificially engineered PD-1, CTLA-4, A20, DGK ⁇ , DGK ⁇ , FAS, EGR2, PPP2R2D, PSGL-1, KDM6A, TET2, etc. It is intended to provide guide nucleic acids and editor proteins.
- the present invention relates to an artificially engineered immune system having an improved immune effect. More specifically, it relates to an artificially modified immune system, including artificially engineered immunoregulatory elements and cells comprising the same.
- the present invention provides immunoregulatory elements genetically engineered or modified for specific purposes.
- an "immunoregulatory element” is a substance that functions in the formation and performance of an immune response and includes all of the various substances that may have an unnatural, ie, artificially engineered, immune response regulatory function. For example, it may be a gene or protein expressed in immune cells, genetically engineered or modified.
- the immunoregulatory element may function in relation to activation or inactivation of immune cells. Can function to suppress immune responses. It can function to promote an immune response. For example, it may be an immune cell growth regulator, an immune cell death regulatory element, an immune cell dysfunction element, or a cytokine secretion element.
- an immunomodulatory element for example, genetically engineered or modified, PD-1 gene, CTLA-4 gene, TNFAIP3 (A20) gene, DGKA gene, DGKZ gene, FAS gene, EGR2 gene , PPP2R2D gene, TET2 gene, PSGL-1 gene, KDM6A gene.
- the present invention may comprise two or more genes genetically engineered or modified as an immunoregulatory element.
- PD-1 gene CTLA-4 gene, TNFAIP3 (A20) gene, DGKA gene, DGKZ gene, FAS gene, EGR2 gene, PPP2R2D gene, TET2 gene, PSGL-1 gene, and KDM6A gene
- TNFAIP3 A20 gene
- DGKA gene DGKA gene
- DGKZ gene FAS gene
- EGR2 gene PPP2R2D gene
- TET2 gene PSGL-1 gene
- KDM6A gene Two or more genes selected can be manipulated or modified.
- Preferred examples of the invention may be genetically engineered or modified TNFAIP3, DGKA, DGKZ, FAS, EGR2, PSGL-1, KDM6A genes.
- Modifications in the nucleic acid sequence can be artificially manipulated by, but not limited to, guide nucleic acid-editor protein complexes.
- Guide nucleic acid-editor protein complex means a complex formed through the interaction of a guide nucleic acid and an editor protein, and the nucleic acid-protein complex includes a guide nucleic acid and an editor protein.
- Guide nucleic acid-editor protein complexes can modify a subject.
- the subject may be a target nucleic acid, gene, chromosome or protein.
- the gene is an immunoregulatory gene artificially manipulated by a guide nucleic acid-editor protein complex.
- It may be an artificially engineered immunomodulatory gene characterized in that it comprises a.
- the modification of the nucleic acid can occur in the promoter region of the gene.
- the modification of the nucleic acid can occur in the exon region of the gene. In one embodiment, the modification may occur in a region within the top 50% of the coding regions of the gene.
- the modification of the nucleic acid can occur in the intron region of the gene.
- the modification of the nucleic acid can occur in the enhancer region of the gene.
- the PAM sequence can be, for example, one or more of the following sequences (described in the 5 'to 3' direction).
- N is A, T, C or G
- N is each independently A, T, C or G, R is A or G, and Y is C or T;
- NNAGAAW N is each independently A, T, C or G, and W is A or T;
- N are each independently A, T, C, or G;
- N is each independently A, T, C or G, R is A or G and Y is C or T);
- TTN (N is A, T, C or G).
- the present invention provides SEQ ID NO: 1 of the nucleic acid sequence of at least one gene selected from PD-1, CTLA-4, A20, DGK ⁇ , DGK ⁇ , FAS, EGR2, PPP2R2D, PSGL-1, KDM6A, and TET2.
- guide nucleic acids capable of forming complementary binding to target sequences from 289 to 289, respectively.
- one or more guide nucleic acids selected from the following groups may be provided:
- a guide nucleic acid capable of forming a complementary bond to a target sequence of SEQ ID NOs: 6 and 11, respectively, in the A20 gene nucleic acid sequence;
- a guide nucleic acid capable of forming a complementary bond to a target sequence of SEQ ID NOs: 87 and 89, respectively, of the PD-1 gene nucleic acid sequence;
- a guide nucleic acid capable of forming a complementary bond to a target sequence of SEQ ID NOs: 109, 110, 111, 112, and 113 of the DGK ⁇ gene nucleic acid sequence, respectively;
- a guide nucleic acid capable of forming a complementary bond to a target sequence of SEQ ID NOs: 126, 128, and 129, respectively, of the TET-2 gene nucleic acid sequence;
- the guide nucleic acid may be, but is not limited to, 18 to 25 bp, 18 to 24 bp, 18 to 23 bp, 19 to 23 bp, 19 to 23 bp, or 20 to 23 bp.
- the present invention may provide artificially engineered immune cells comprising one or more of the artificially engineered immunoregulatory genes and products expressed therefrom.
- immune cell is a cell involved in an immune response, and includes all cells which are directly or indirectly involved in the immune response and their cells prior to their differentiation.
- the stem cells are derived from embryonic stem cells, adult stem cells, induced pluripotent stem cells (iPS cells) or induced pluripotent stem cells having the ability to replicate and differentiate.
- Cells eg, an iPS cell generated from a subject, manipulated to alter (eg, induce a mutation in).
- the immune cell may be a CD3 positive cell.
- it may be a T cell or a CAR-T cell.
- the immune cell may be a CD56 positive cell.
- it may be NK cells, such as NK92, primary NK cells.
- the immune cells can be CD3 and CD56 double positive cells.
- it may be a Natural Killer T (NKT) cell or a Cytokine Induced Killer cell (CIK).
- NKT Natural Killer T
- CIK Cytokine Induced Killer cell
- the cells may be T cells, such as CD8 + T cells (eg, CD8 + naive T cells, CD8 + effector T cells, central memory T cells, or effector memory T cells), CD4 + T cells, natural killer T cells ( NKT cells), regulatory T cells (Treg), stem cell memory T cells, lymphocyte progenitor cells, hematopoietic stem cells, natural killer cells (NK cells), dendritic cells, cytokine-induced killer cells (CIK) Killer cell), PBMC (Peripheral blood mononuclear cell), monocytes (monocyte), macrophage (macrophage), NKT (Natural Killer T) cells, etc. may be one or more selected from the group consisting of.
- the immune cells may be T cells, CAR-T cells, NK cells or NKT cells and the like.
- Immune cells can be artificially engineered to inhibit or inactivate the activity of the immunoregulatory genes.
- the immune cell may further comprise a chimeric antigen receptor (CAR).
- CAR chimeric antigen receptor
- the T cells may further comprise chimeric antigen receptors (CARs) or engineered TCRs (T-cell receptors).
- CARs chimeric antigen receptors
- T-cell receptors engineered TCRs
- Immune cells may further comprise guide nucleic acid-editor protein complexes or nucleic acid sequences encoding them.
- the editor protein is a Cas9 protein derived from Streptococcus pyogenes, a Cas9 protein derived from Campylobacter jejuni, a Cas9 protein derived from Streptococcus thermophilus, Streptococcus aureus It may be at least one selected from the group consisting of Cas9 protein from Streptococcus aureus, Cas9 protein derived from Neisseria meningitidis, and Cpf1 protein. In one example, it may be a Cas9 protein from Streptococcus pyogenes or a Cas9 protein from Campylobacter jejuni.
- the guide nucleic acid binds complementarily with a portion of the nucleic acid sequence of one or more genes selected from the group consisting of PD-1, CTLA-4, A20, DGK ⁇ , DGK ⁇ , FAS, EGR2, PPP2R2D, PSGL-1, KDM6A, and TET2, respectively. Can be formed. 0 to 5, 0 to 4, 0 to 3, 0 to 2 mismatching.
- the guide nucleic acid may be a nucleotide forming a binding complementary to at least one of the target sequences of SEQ ID NOs: 1 to 289 in Table 1.
- SEQ ID NOs: 6 and 11 A20
- SEQ ID NOs: 19, 20, 21, and 23 SEQ ID NO: 25
- EGR2 SEQ ID NO: 64
- PPP2R2D SEQ ID NOs: 87 and 89
- PD-1 SEQ ID NOs: 109, 110, 111, 112 and 113
- DGK ⁇ SEQ ID NOs: 126, 128 and 129
- TERT-2 SEQ ID NO: 182
- SEQ ID NOs: 252, 254, 257 and 264 (FAS) And nucleotides each forming a complementary bond to at least one of the target sequences of SEQ ID NO: 285 (KDM6A).
- the immune cell may comprise one or more of artificially engineered DGK ⁇ and DGK ⁇ genes, in which modifications in nucleic acid sequences have occurred.
- the immune cell may comprise a combination of artificially engineered DGK ⁇ and DGK ⁇ genes that have undergone modifications in nucleic acid sequences.
- a composition that gives rise to a desired immune response. It may be referred to as a pharmaceutical composition or a therapeutic composition.
- the invention comprises SEQ ID NO: 1 of the nucleic acid sequence of at least one gene selected from the group consisting of PD-1, CTLA-4, A20, DGK ⁇ , DGK ⁇ , FAS, EGR2, PPP2R2D, PSGL-1, KDM6A, and TET2 Guide nucleic acids each capable of forming a complementary bond to a target sequence of 289 to 289; And editor proteins or nucleic acids encoding them
- composition for genetic manipulation comprising a.
- the invention relates to immune cells isolated from the human body.
- Cas9 protein from Streptococcus pyogenes Cas9 protein from Campylobacter jejuni, Cas9 protein from Streptococcus thermophilus, Streptococcus aureus
- the guide nucleic acid and the editor protein may be present in one or more vectors in the form of a nucleic acid sequence, or may be present by forming a complex by combining the guide nucleic acid and the editor protein.
- the contacting step may be performed in vivo or ex vivo.
- the contacting step may be performed by one or more methods selected from electroporation, liposomes, plasmids, viral vectors, nanoparticles, and protein translocation domain (PTD) fusion protein methods.
- electroporation liposomes
- plasmids plasmids
- viral vectors viral vectors
- nanoparticles and protein translocation domain (PTD) fusion protein methods.
- PTD protein translocation domain
- the viral vector may be one or more selected from the group consisting of retroviruses, lentiviruses, adenoviruses, adeno-associated viruses (AAV), vaccinia virus, poxvirus and herpes virus.
- retroviruses lentiviruses
- adenoviruses lentiviruses
- AAV adeno-associated viruses
- vaccinia virus poxvirus and herpes virus.
- the sequence of said immune cell target position in a subject by sequencing one or more genes of PD-1, CTLA-4, A20, DGK ⁇ , DGK ⁇ , FAS, EGR2, PPP2R2D, PSGL-1, KDM6A, and TET2. Provides a way to provide information about
- a kit for genetic manipulation comprising:
- Cas9 protein from Streptococcus pyogenes Cas9 protein from Campylobacter jejuni
- Cas9 protein from Streptococcus thermophilus Cas9 protein from Streptococcus aureus
- An editor protein or nucleic acid encoding the same which is at least one selected from the group consisting of Cas9 protein from Streptococcus aureus, Cas9 protein derived from Neisseria meningitidis, and Cpf1 protein.
- kits can be used to artificially manipulate the gene of interest.
- the invention provides all aspects of a disease therapeutic use using an immunotherapy approach comprising administration of artificially engineered cells, such as genetically engineered immune cells or stem cells, to a subject.
- artificially engineered cells such as genetically engineered immune cells or stem cells
- it is useful for adoptive immunotherapy.
- the subject to be treated may be a mammal including humans, primates such as monkeys, rodents such as mice, rats and the like.
- Effective immune cell therapeutics can be obtained by artificially engineered immunoregulatory elements and an immune system that has been artificially modified in function by cells comprising the same.
- the survival, proliferation, persistence, cytotoxicity, and cytokine secretion of immune cells Immune efficacy, such as involved in release and / or infiltration, may be improved.
- FIG. 1 is a graph showing CD25 MFI (median fluorescence intensity) in cells knocked out of DGK-alpha gene using sgRNA for DGK-alpha (# 11; denoted DGK-alpha # 11).
- FIG. 2 is a graph showing CD25 MFI in cells knocked out of A20 gene using sgRNA for A20 (labeled # 11; A20 # 11).
- EGR2 # 1 is a graph showing CD25 MFI in cells knocked out of the EGR2 gene using sgRNA for EGR2 (# 1; denoted as EGR2 # 1).
- PPP2R2D # 10 is a graph showing CD25 MFI in cells knocked out of PPP2R2D gene using sgRNA for PPP2R2D (# 10; denoted PPP2R2D # 10).
- FIG. 5 shows A20 using sgRNA for DGK-alpha (# 11; denoted DGK-alpha # 11) and cells knocked out of the DGKalpha gene, sgRNA for A20 (# 11; denoted A20 # 11).
- FIG. 6 shows a cell knocked out of the DGKalpha gene using sgRNA for DGK-alpha (# 11; denoted DGK-alpha # 11), sgRNA for DGK-alpha (in combination with # 8 and # 11; DGKalpha # 8 + Cells knocked out of the DGK-alpha gene using the sgRNA for DGK-zeta (# 5; marked with DGK-zeta # 5), and for A20. Cells knocked out of the A20 gene using sgRNA (labeled # 11; A20 # 11)
- FIG. 7 shows a cell knocked out of the DGK-alpha gene using DGK-alpha # 11, a cell knocked out of the DGK-alpha gene using DGKalpha # 8 + 11, and a DGK-zeta using DGK-zeta # 5.
- FIG. 8A relates to knockout results of the CRISPR / Cas9 mediated DGK gene in human primary T cells,
- A Gene knockout timeline (human cell activation by CD3 / CD28 beads, 139 CAR in human primary T cells).
- B Knockout of DGK gene using lentiviral delivery, electroporation d)
- B Indel efficiency for DGK ⁇ and DGK ⁇ using the Mi-seq system.
- FIG. 8B shows the results of off-target analysis. The graph shown.
- FIG. 9a shows the effector and proliferation of CAR-T cells by knockout of the DGK gene.
- A Killing activity of 139 CAR-T cells according to 7-AAD positive U87vIII cell measurement using flow cytometry. activity) evaluation result
- B The result of cytokine secretion analysis by ELISA (IFN- ⁇ , IL-2 kit, Biolegend)
- Figure 9b is a graph showing the results of evaluation of proliferative capacity of 139 CAR T-cells using flow cytometry.
- FIG. 10 relates to the results of DGKs knockout enhancing 139 CAR expression and amplifying CD3 end signaling after antigen exposure, (A) for phosphorylated ERK signal of 139 CAR-T cells, stimulated with CD3 / CD28 beads Western blot results, (B) 139 CAR expression results using flow cytometry: the left side is the expression of CAR according to antigen exposure, the right is a graph showing the comparison of CAR expression after 3 days of antigen exposure.
- Figure 11 relates to the results of DGKs knockout does not induce tonic activation and T-cell exhaustion, (A) evaluation of IFN- ⁇ secretion by ELISA, (B) PD- which is an Exhaustion marker in CAR-positive T-cells Graph showing 1 (left) and TIM-3 (right) analysis results.
- FIG. 12 relates to a result of DGK-knocked-out T-cells avoiding the immunosuppressive effects of TGF- ⁇ and PGE2.
- Evaluation of Killing Activity, IFN- ⁇ Secretion and IL-2 Secretion of DGK ⁇ CAR-T Cells (B) Killing Activity of 139 CAR-T and 139 DGK ⁇ CAR-T Cells with or Without PGE2 (0.5 ug / mL) activity), IFN- ⁇ secretion and IL-2 secretion evaluation results.
- Figure 13 relates to the effect of knockout efficiency and effector function of DGK ⁇ mediated by CRISPR / Cas9 in human NK cells
- (A) and (B) are NK-92 cells and human primary using Mi-seq system It is a graph showing the knockout efficiency analysis in NK cells
- (C) is a graph showing the killing activity of NK-92 by measuring 7-AAD positive Raji cells.
- Figure 14 shows the knockout efficiency of DGK ⁇ and DGK ⁇ by CRISPR / Cas9 mediated human NKT cells, (A) indel efficiency, (B) cell growth (C) cell viability evaluation results and (D) protein levels Western blot experiment results for confirming the expression is shown.
- Figures 17a-17c show assay results for hPSGL-1 sgRNA screening in Jurkat cells, indel efficiency and extent of Jurtat cells not expressing PSGL-1 after knockout (17a) and expression on Jurkat cell surface after knockout
- the graphs 17b and 17c showing the expression level of PSGL-1.
- the present invention is directed to artificially engineered immune systems with improved immune effects. More specifically, it relates to an artificially modified immune system, including artificially engineered immunoregulatory elements and cells comprising the same.
- Immunomodulatory factor ( immune regulatory factor )
- an "immunoregulatory element” is a substance that functions in the formation and performance of an immune response and includes all of the various substances that may have an unnatural, ie, artificially engineered, immune response regulatory function. For example, it may be a gene or protein expressed in immune cells, genetically engineered or modified.
- artificially manipulated refers to a state in which an artificial modification has been made, not a state as it occurs in nature.
- genetically engineered refers to a case where an artificial genetic modification is made to a biological or non-living material referred to in the present invention, for example, to artificially modify a genome for a specific purpose.
- Genes and / or gene products polypeptides, proteins, etc.
- the present invention provides immunoregulatory elements that are genetically engineered or modified for specific purposes.
- immunomodulatory elements Since the elements divided below are only examples of immunomodulatory elements, the present invention does not limit the types of immunoregulatory elements encompassed by the present invention.
- the genes or proteins listed below may not only have one type of immunoregulatory function, but may have multiple types of functions. In addition, two or more immunomodulatory elements may be provided as necessary.
- an “immune cell activity regulatory element” is an element that functions to modulate the degree or activity of an immune response, eg, a gene or protein that functions to modulate the degree or activity of an immune response, eg, genetically engineered or modified. Can be.
- Immune cell activation regulatory elements may function in the activation or inactivation of immune cells.
- Immune cell activation regulatory elements may function to promote or enhance an immune response.
- Immune cell activation regulatory elements may function to inhibit immune responses.
- Immune cell activity-regulating elements may function in conjunction with channel proteins and receptors on cell membranes to regulate signal transduction and protein synthesis and degradation.
- the immune cell activity regulatory element may be PD-1.
- PD-1 gene (also referred to as PDCD1 gene; hereafter PD-1 gene and PDCD1 gene are used to mean the same gene) is the protein PD-1 (Programmed cell death protein) also called CD279 (cluster of differentiation 279) Means a gene (full length DNA, cDNA or mRNA).
- the PD-1 gene may be, but is not limited to, one or more selected from the group consisting of: a gene encoding human PD-1 (eg, NCBI Accession No. NP_005009.2, etc.) such as NCBI Accession No. PD-1 gene represented by NM_005018.2, NG_012110.1 and the like.
- the immune cell activity regulatory element may be CTLA-4.
- CTLA-4 cytotoxic T-lymphocyte-associated protein 4
- CTLA-4 also called CD152 (cluster of differentiation 152).
- the CTLA-4 gene may be one or more selected from the group consisting of, but is not limited to: a gene encoding human CTLA-4 (eg, NCBI Accession No. NP_001032720.1, NP_005205.2, etc.)
- the CTLA-4 gene represented by NCBI Accession No. NM_001037631.2, NM_005214.4, NG_011502.1 and the like.
- the immune cell activity regulatory element may be CBLB.
- the immune cell activity regulatory element may be PSGL-1.
- the immune cell activity regulatory element may be ILT2.
- the immune cell activity regulatory element may be KIR2DL4.
- the immune cell activity regulatory element may be SHP-1.
- the genes may be derived from mammals including humans, primates such as monkeys, rodents such as rats and mice.
- immune cell activating elements may function to promote an immune response.
- the immune cell activity regulating element may be an immune cell growth regulating element.
- Immuno cell growth regulator refers to an element that functions to regulate the growth of immune cells by regulating protein synthesis and the like in immune cells, and may be, for example, genes or proteins expressed in immune cells.
- the immune cell growth regulator may function in relation to transcription of DNA, translation of RNA, and cell differentiation.
- immune cell growth regulatory elements may be genes or proteins involved in the expression pathways of NFAT, I ⁇ B / NF- ⁇ B, AP-1, 4E-BP1, eIF4E, S6.
- the immune cell growth regulator may be DGK-alpha.
- DGKA Dgk-alpDha gene means a gene (full length DNA, cDNA or mRNA) encoding DGKA (Diacylglycerol kinase alpha).
- the DGKA gene may be one or more selected from the group consisting of, but is not limited to: human DGKA (eg, NCBI Accession No. NP_001336.2, NP_958852.1, NP_958853.1, NP_963848.1, etc.) Genes encoding proteins, such as NCBI Accession No. DGKA gene represented by NM_001345.4, NM_201444.2, NM_201445.1, NM_201554.1, NC_000012.12 and the like.
- the immune cell growth regulator may be DGK-zeta.
- DGKZ (Dgk-zeta) gene means a gene (full length DNA, cDNA or mRNA) encoding DGKZ (Diacylglycerol kinase zeta).
- the DGKZ gene may be one or more selected from the group consisting of, but is not limited to: human DGKZ (eg, NCBI Accession No. NP_001099010.1, NP_001186195.1, NP_001186196.1, NP_001186197.1, NP_003637 .2, NP_963290.1, NP_963291.2, etc.), for example, NCBI Accession No.
- DGKZ genes represented by NM_001105540.1, NM_001199266.1, NM_001199267.1, NM_001199268.1, NM_003646.3, NM_201532.2, NM_201533.3, NG_047092.1 and the like.
- the immune cell growth regulator may be EGR2.
- EGR2 gene refers to a gene (full length DNA, cDNA or mRNA) encoding EGR2 (Early growth response protein 2).
- the EGR2 gene may be one or more selected from the group consisting of, but is not limited to:
- the immune cell growth regulator may be EGR3.
- the immune cell growth regulator may be PPP2R2D.
- the immune cell growth regulator may be A20 (TNFAIP3).
- the immune cell growth regulator may be PSGL-1.
- the genes may be derived from mammals including humans, primates such as monkeys, rodents such as rats and mice.
- the immune cell activity regulating element may be an immune cell death regulating element.
- immune cell death regulatory element is an element that functions in killing immune cells, and may be a gene or protein expressed in immune cells.
- the immune cell death regulatory element may have a function related to cell death (apoptosis) or cell necrosis (necrosis) of immune cells.
- the immune cell death regulatory element may be a caspase cascade-associated protein or gene.
- the immune cell death regulatory element may be Fas.
- Fas When referring to a protein or gene hereinafter, it is natural for a person skilled in the art to manipulate a receptor and a binding portion on which the protein or gene acts.
- the immune cell death regulatory element may be a death domain-associated protein or gene. At this time, the immune cell death regulatory element may be Daxx.
- the immune cell death regulatory element may be a Bcl-2 family protein.
- the immune cell death regulatory element may be a BH3-only family protein.
- the immune cell death regulatory element may be Bim.
- the immune cell death regulatory element may be Bid.
- the immune cell death regulatory element may be BAD.
- the immune cell death regulatory element may be a ligand or a receptor located in the immune extracellular membrane.
- the immune cell death regulatory element may be PD-1.
- the immune cell death regulatory element may be CTLA-4.
- the immune cell activity regulating element may be an immune cell exhaustion regulating element.
- immune cell loss factor is an element that functions in relation to the progressive loss of function of an immune cell, and may be a gene or protein expressed in immune cells that functions.
- the immune cell dysfunction element may function to help the transcription or translation of genes involved in the inactivation of immune cells.
- the function of assisting transcription may be a function of demethylation of the gene.
- genes involved in inactivation of immune cells include genes of the immune cell activation regulatory element.
- the immune cell loss factor may be TET2.
- TET2 Genes encoding human TET2 (e.g., NCBI Accession No. NP_001120680.1, NP_060098.3, etc.), such as NCBI Accession NM_001127208.2, No. TET2 gene represented by NM_017628.4, NG_028191.1, etc.
- Immune cell dysfunction may play a role in the excessive growth of immune cells. Immune cells that only grow excessively and do not regenerate lose their function.
- the immune cell loss factor may be Wnt.
- a protein or gene hereinafter, it is natural for a person skilled in the art to manipulate a gene in the protein or a signal transduction pathway in which the protein is included and a receptor or binding portion to which the gene functions.
- the immune cell dysfunction element may be Akt.
- Akt Akt
- the immune cell activity regulating element may be a cytokine production regulating element.
- a "cytokine secretory element” may be a gene or protein expressed in immune cells that functions as a component involved in cytokine secretion of immune cells.
- Cytokine is a generic term for proteins secreted by immune cells and is a signaling protein that plays an important role in the body. Involved in infection, immunity, inflammation, trauma, rot, cancer, etc. Cytokines can be secreted from cells and then affect other cells or the cells themselves. For example, it may induce proliferation of macrophages or promote differentiation of secretory cells themselves. However, when secreted in excessive amounts, problems such as attacking normal cells appear, so proper secretion of cytokines in the immune response is also important.
- Cytokine secretion elements are preferably, for example, TTNF ⁇ , IFN- ⁇ , TGF- ⁇ , IL-2, IL-4, IL-10, IL-13, IL-1, IL-6, IL-12, Gene or protein in IL-7, IL-15, IL-17, IFN- ⁇ .
- the cytokine may function to transmit a signal to other immune cells to induce or kill different antigen-bearing cells recognized by the immune cells.
- the cytokine secretion element may preferably be a gene or protein in the gene pathway related to IL-2 secretion.
- the immunoregulatory element can mean a group of molecules expressed in immune cells. These molecules can act effectively to down / up control or inhibit / promote the immune response.
- immunoreactive checkpoint as a group of molecules expressing T cells is a Programmed Death1 (PD-1. PDCD1 or CD279, accession number: NM_005018) cytotoxic T lymphocyte antigen 4 (directly inhibiting immune cells).
- CTLA-4 or CD152 GenBank accession number AF414120.1
- LAG3 CD223, accession number: NM_002286.5
- Tim3 HAVCR2, GenBank accession number: JX049979.1
- BTLA CD272, accession number: NM_181780.3
- BY55 CD160, GenBank accession number: CR541888.1
- TIGIT IVSTM3, accession number: NM_173799
- LAIR1 CD305, GenBank accession number: CR542051.1
- SIGLEC10 GeneBank accession number: AY358337.1
- 2B4 CD244, accession number: NM_001166664.1
- PPP2CA PPP2CB, PTPN6, PTPN22, CD96, CRTAM, SIGLEC7, SIGLEC9, TNFRSF10B, TNFRSF10A, CASP8, CASP10, CASP3, CASP6, CASP7, FADD, FASAD TFRBRII
- an immunomodulatory element for example, genetically engineered or modified, PD-1 gene, CTLA-4 gene, TNFAIP3 (A20) gene, DGKA gene, DGKZ gene, FAS gene, EGR2 gene , PPP2R2D gene, TET2 gene, PSGL-1 gene, and KDM6A gene.
- the present invention may comprise two or more genes genetically engineered or modified as an immunoregulatory element.
- PD-1 gene CTLA-4 gene, TNFAIP3 (A20) gene, DGKA gene, DGKZ gene, FAS gene, EGR2 gene, PPP2R2D gene, TET2 gene, PSGL-1 gene, and KDM6A gene
- TNFAIP3 A20 gene
- DGKA gene DGKA gene
- DGKZ gene FAS gene
- EGR2 gene PPP2R2D gene
- TET2 gene PSGL-1 gene
- KDM6A gene Two or more genes selected can be manipulated or modified.
- Preferred examples of the invention may be genetically engineered or modified TNFAIP3, DGKA, DGKZ, FAS, EGR2, PSGL-1, KDM6A genes.
- Such genetic manipulation or modification can be obtained by artificially inserting, deleting, replacing, or inverting mutations in some or all regions of the genomic sequence of a wild type gene.
- the genetic manipulation or modification may be obtained by fusing the manipulation or modification of two or more genes.
- such genetic manipulation or modification may inactivate the gene so that the protein encoded from the gene is not expressed in the form of a protein having an original function.
- such genetic manipulation or modification may further enable the gene to be expressed so that the protein encoded from the gene is expressed in the form of a protein having an improved function than the original function.
- the function of a protein encoded by a particular gene is A
- the function of the protein expressed by the engineered gene may be completely different from A or have additional functions (A + B) including A together. have.
- such genetic manipulation or modification may be such that two or more proteins are expressed in a fused form using two or more genes having different or complementary functions.
- such genetic manipulation or modification may be used to allow two or more proteins to be expressed in separate and independent forms in cells using two or more genes having different or complementary functions.
- Gene information can be obtained from known databases such as GenBank of the National Center for Biotechnology Information (NCBI).
- the manipulation or modification of the gene may be induced by one or more of the following:
- 'target gene' a gene of modification
- nucleotides of the target gene such as 1 to 30, 1 to 27, 1 to 25, 1 to 23, 1 to Deletion of 20, 1 to 15, 1 to 10, 1 to 5, 1 to 3, or 1 nucleotides
- nucleotides of the target gene such as 1 to 30, 1 to 27, 1 to 25, 1 to 23, 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 To three, or one, nucleotide substitution with a nucleotide different from the original (wild-type), and one or more nucleotides, such as 1 to 30, 1 to 27, 1 to 25, 1 to 23, 1 to 20 Insertion of a dog, 1-15, 1-10, 1-5, 1-3, or 1 nucleotides, each independently selected from A, T, C and G, into any position of the target gene .
- the modified part of the target gene is at least 1bp, 3bp or more, 5bp or more, 7bp or more, 10bp or more, 12bp or more, 15bp or more, 17bp or more, 20bp or more, for example, 1bp to 30bp, 3bp to 30bp, 5bp to 30bp, 7bp to 30bp, 10bp to 30bp, 12bp to 30bp, 15bp to 30bp, 17bp to 30bp, 20bp to 30bp, 1bp to 27bp, 3bp to 27bp, 5bp to 27bp, 7bp to 27bp, 10bp to 27bp, 12bp to 27bp, 15bp to 27bp, 17bp to 27bp, 20bp to 27bp, 1bp to 25bp, 3bp to 25bp, 5bp to 25bp, 7bp to 25bp, 10bp to 25bp,
- One aspect of the invention is a cell comprising said artificially engineered immunomodulatory elements.
- the cells are, but are not limited to, immune cells and stem cells.
- an “immune cell” of the present invention is a cell involved in an immune response, and includes all cells directly or indirectly involved in the immune response and their cells before differentiation.
- Immune cells may have functions of secretion of cytokines, differentiation into other immune cells, and cytotoxicity. Immune cells also include cells from which natural mutations have occurred.
- Immune cells differentiate from hematopoietic stem cells in the bone marrow and largely include lymhoid progenitor cells and myeloid progenitor cells. T cells and B cells responsible for acquired immunity by differentiation of lymphoid progenitor cells; And macrophages, eosinophils, neutrophils, basophils, granulocytes, megakaryocytes, erythrocytes, etc., differentiated from myeloid progenitor cells.
- the cells may be T cells, such as CD8 + T cells (eg, CD8 + naive T cells, CD8 + effector T cells, central memory T cells, or effector memory T cells), CD4 + T cells, natural killer T cells ( NKT cells), regulatory T cells (Treg), stem cell memory T cells, lymphocyte progenitor cells, hematopoietic stem cells, natural killer cells (NK cells), dendritic cells, cytokine-induced killer cells (CIK) Killer cell), PBMC (Peripheral blood mononuclear cell), monocytes (monocyte), macrophage (macrophage), NKT (Natural Killer T) cells, etc. may be one or more selected from the group consisting of.
- CD8 + T cells eg, CD8 + naive T cells, CD8 + effector T cells, central memory T cells, or effector memory T cells
- CD4 + T cells such as CD8 + T cells (eg, CD8 + naive T cells, CD
- Macrophages and dendritic cells are referred to as "antigen presenting cells” or “APCs”, which are specialized cells that can activate T cells when the major histocompatibility complex (MHC) receptors on their cell surface interact with TCR on the T cell surface.
- APCs antigen presenting cells
- MHC major histocompatibility complex
- any hematopoietic stem cell or immune system cell can be converted to APC by introducing a nucleic acid molecule that expresses an antigen recognized by a TCR or other antigen binding protein (eg, a CAR).
- said immune cell can be a cell used in immunotherapy by inactivating or exchanging a gene that synthesizes a protein (eg, an immune checkpoint protein) that is involved in MHC recognition and / or immune function.
- a protein eg, an immune checkpoint protein
- said immune cells can further comprise polynucleotides encoding receptors of single chain and multiple subunits (eg, CAR, TCR) for specific cellular recognition.
- polynucleotides encoding receptors of single chain and multiple subunits (eg, CAR, TCR) for specific cellular recognition.
- the immune cells of the present invention comprise blood (eg, peripheral blood), stem cells (eg, embryonic stem cells, induced pluripotent stem cells, etc.) of healthy donors and / or patients. ), Cord blood, bone marrow, and the like may be derived from immune cells, and may be manipulated in vitro.
- blood eg, peripheral blood
- stem cells eg, embryonic stem cells, induced pluripotent stem cells, etc.
- Cord blood eg, bone marrow, and the like may be derived from immune cells, and may be manipulated in vitro.
- the immune cells can be CD3 positive cells.
- it may be a T cell or a CAR-T cell.
- CD3 is a receptor in which TCR and various proteins exist as a complex on the surface of T cells. Five proteins, called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ chains, form CD3, which, together with TCR, exist as TCR / CD3 complexes in the ⁇ : ⁇ or ⁇ : ⁇ states. They are known to have a function of signal transduction in the cell upon antigen recognition of T cells.
- the immune cells can be CD56 positive cells.
- it may be NK cells, such as NK92, primary NK cells.
- NK cells have the third largest number of immune cells, and about 10% of peripheral blood immune cells are NK cells.
- NK cells have CD56 and CD16 and mature in the liver or bone marrow.
- perforin can be sprayed on the cell membrane to dissolve and puncture the cell membrane, and granzyme is sprayed on the cell membrane to dissolve the cytoplasm and cause apoptosis or inside the cell. Infusion of water and salt causes necrosis, which kills many cancer cells.
- NK cells are well known as cells in which foreign genetic material is not easily introduced.
- said immune cells can be CD3 and CD56 double positive cells.
- it may be a natural killer T (NKT) or cytokine-induced killer cell (CIK) cell.
- Natural killer T (NKT) or cytokine-induced killer cell (CIK) cells are immune cells that express both CD3, a T cell marker, and a CD56 molecule, a natural killer cell (NK cell) marker. Since it is derived from T cells and has both the characteristics and functions of NK cells, tumor cells are killed regardless of the major histocompatibility complex (MHC).
- natural killer T (NKT) cells are cells expressing NK1.1 or NKR-P1A (CD161), which are receptors for T cells (TCR) and NK cell-specific surface markers.
- NKT cells recognize glycolipids presented by CD1d, a monomorphic protein with a structure similar to MHC class I. NKT cells secrete various types of cytokines such as IL-4, IL-13, IL-10 and IFN- ⁇ when activated by ligands such as ⁇ -GalCer. In addition, the NKT cells have anti-tumor activity.
- CIK cells are a kind of immune cells that proliferate when blood is collected and treated with interleukin 2 and CD3 antibodies in vitro for 2-3 weeks, and are positive for CD3 and CD56. CIK cells produce large amounts of IFN- ⁇ and TNF- ⁇ .
- the cells are embryonic stem cells, adult stem cells, induced pluripotent stem cells (iPS cells) or induced pluripotent stem cells with self-replicating and differentiating abilities.
- Cells may be derived from (eg, an iPS cell derived cell).
- Cells as preferred examples of the invention include engineered or modified genes that are immunoregulatory elements.
- the cell may comprise part or all of the engineered or modified gene; Or expression products thereof.
- the protein encoded from the gene may be a cell in which it is not expressed in the form of a protein with its original function.
- the protein encoded from the gene may be a cell expressed in the form of a protein having an improved function than the original function.
- such genetic manipulation or modification may be such that the protein encoded from this gene is expressed in the form of a protein that functions in and / or other than its original function.
- it may be a cell in which two or more proteins are expressed in a modified form using two or more genes having different or complementary functions by such genetic manipulation or modification.
- such genetic manipulation or modification may be immune cells with high cytokine production or secretion of three types of IL-2, TNF ⁇ and IFN ⁇ .
- the cells of the present invention may further comprise a configuration as follows.
- Cells of the invention may comprise an "immune receptor".
- an “immune receptor” is a receptor present on the surface of an artificially engineered or modified immune cell, and refers to a substance that participates in an immune response, such as an antigen, that recognizes and functions a specific function.
- the receptor may be wild or artificially manipulated
- the receptor may have affinity for the antigen.
- the receptor may have the ability to recognize the structure of the MHC structural protein and the antigen disclosed in the structural protein.
- Receptors can generate immune response signals.
- Immunune response signal means any signal that occurs during the immune response.
- the immune response signal may be a signal related to the growth and differentiation of immune cells.
- the immune response signal may be a signal associated with the death of immune cells.
- the immune response signal may be a signal related to the activity of immune cells.
- the immune response signal may be a signal associated with the assistance of the immune response.
- the immune response signal may be a signal that regulates expression of a target gene.
- the immune response signal may be to promote or inhibit the synthesis of cytokines.
- the immune response signal may be to promote or inhibit the secretion of cytokines.
- the immune response signal may be a signal that helps growth or differentiation of other immune cells.
- the immune response signal may be a signal that modulates the activity of other immune cells.
- the immune response signal may be a signal that attracts other immune cells to the location where the signal occurs.
- the receptor may be a T cell receptor (TCR).
- TCR T cell receptor
- the cell may be modified to include a specific T cell receptor (TCR) gene (e.g., TRAC or TRBC gene).
- TCR T cell receptor
- the TCR may be used for a tumor associated antigen (eg, MART1 (melanoma antigen recognized by T cells 1, MAGEA3 (melanoma-associated antigen3), NY-ESOl), NYESOl,, carcinoembryonic antigen (CEA), GP100, etc.). It may have binding specificity.
- the receptor may be a toll like receptor (TLR).
- TLR toll like receptor
- the receptors may be CD4 and CD8, which are co-receptors involved in MHC-limiting T cell activation.
- the receptor may be CTLA-4 (CD152).
- the receptor may be CD28.
- the receptor may be CD137, 4-1BB, a receptor that amplifies T cell responses.
- the receptor may be CD3 ⁇ , a signaling component of T cell antigen receptor.
- the receptor may be a CAR (Chimeric Antigen Receptor).
- the receptor may be an artificially engineered artificial receptor (artificial receptor)
- Articles refers to a functionally functional and specific function of an antigen that is artificially produced, rather than a wild type receptor.
- These artificial receptors may contribute to the improvement of the immune response by improving the ability to recognize a specific antigen or by generating an enhanced immune response signal.
- the artificial receptor may have the following configuration as an example.
- Artificial receptors include antigen recognition units.
- Antigen recognition part means a site that recognizes an antigen as part of an artificial receptor.
- the antigen recognition unit may be an improved ability to recognize a specific antigen than wild receptors.
- the specific antigen may be an antigen of cancer cells.
- certain antigens may be antigens of general body cells.
- the antigen recognition portion may have affinity with the antigen.
- the antigen recognition unit may generate a signal while binding to the antigen.
- the signal may be an electrical signal.
- the signal may be a chemical signal.
- the antigen recognition unit may include a signal sequence.
- the signal sequence refers to a peptide sequence that allows the protein to be delivered to a specific position during protein synthesis.
- the signal sequence may be located near the N terminus of the antigen recognition portion. In this case, the distance from the N terminal may be about 100 amino acids.
- the signal sequence may be located near the C terminus of the antigen recognition portion. In this case, the distance from the C terminal may be about 100 amino acids.
- the antigen recognition part may have an organic functional relationship with the first signaling part.
- the antigen recognition portion may have homology with the Fab (fragment antigen binding) domain of the antibody.
- the antigen recognition portion may be a single-chain variable fragment (scFv).
- the antigen recognition unit may recognize the antigen by itself or form an antigen recognition construct.
- Antigen recognition constructs must form a specific structure in order to recognize the antigen, and the unit and the combination of the units forming the specific structure can be easily understood by those skilled in the art.
- the antigen recognition construct may also consist of one or two or more units.
- the antigen recognition construct may be a structure in which the units are connected in a line, or may be a structure connected in parallel.
- a structure connected in a line means a form in which two or more units are continuously connected in one direction, and a structure connected in parallel means that two or more units are simultaneously connected to one end of one unit, for example, in different directions. It means a combined form.
- the unit may be an inorganic material.
- the unit may be a biochemical ligand.
- the monomer may have homology with the antigen recognition portion of the wild type receptor.
- the monomer may be homologous to the antibody protein.
- the unit may have a heavy chain or homology with an immunoglobulin.
- the unit may have a light chain or homology with an immunoglobulin.
- the unit may include a signal sequence.
- the unit may be bound by a chemical bond, or may be bound through a specific bond.
- Antigen recognition unit combining part is a site where the antigen recognition unit is combined with each other, it may be an optional configuration that exists when there is an antigen recognition structure consisting of two or more antigen recognition units. .
- the antigen recognition structural unit binding portion may be a peptide. At this time, the binding portion may have a high ratio of serine and threonine.
- the antigen recognition structural unit binding portion may be a chemical binding.
- the antigen recognition structural unit binding portion may help to express the conformation of the antigen recognition structural unit by having a specific length.
- the antigen recognition structural unit binding unit may help the function of the antigen recognition structure by having a specific positional relationship between the antigen recognition structural units.
- the artificial receptor includes the receptor body portion.
- the "receptor body part” is a site that mediates the connection between the antigen recognition unit and the signal generator, and may physically connect the antigen recognition unit and the signal generator.
- the function of the receptor body may be to transmit a signal generated by the antigen recognition unit or the signal generator.
- the structure of the receptor body may optionally have the function of a signal generator.
- the function of the receptor body may be to allow the artificial receptor to be immobilized to immune cells.
- the receptor body may comprise an amino acid helix structure.
- the structure of the receptor body may include a portion homologous to a part of a general receptor protein present in the body.
- the homology can range from 50 to 100%.
- the structure of the receptor body may include a portion homologous to the protein on the immune cell.
- the homology can range from 50 to 100%.
- the receptor body can be a CD8 transmembrane domain.
- the receptor body can be the CD28 transmembrane region.
- the CD28 may function as the second signal generator and the receiver body at the same time.
- the artificial receptor may include a signal generator.
- First signal generator refers to a site that generates an immune response signal as part of an artificial receptor.
- “Second signal generator” refers to a site that interacts with or independently generates an immune response signal as part of an artificial receptor.
- the artificial receptor may include a first signal generator and / or a second signal generator.
- Two or more first and / or second signal generators may be included.
- the first and / or second signaling portion may comprise specific sequence motifs.
- the sequence motif may be homologous to the motif of a cluster of designition (CD) protein.
- the CD protein may be CD3, CD247, CD79.
- the sequence motif may be an amino acid sequence of YxxL / I.
- the sequence motif may be multiplexed into the first and / or second signaling portion.
- the first sequence motif may be located at a position 1 to 200 amino acids away from the start position of the first signal generator.
- the second sequence motif may be at a position 1 to 200 amino acids away from the start position of the second signaling portion.
- the spacing between each sequence motif may be 1 to 15 amino acids in number.
- the spacing between each preferred sequence motif is the number of 6 to 8 amino acids.
- the first and / or second signal generator may be CD3 ⁇ .
- the first and / or second signal generator may be Fc ⁇ RI ⁇ .
- the first and / or second signal generator may generate an immune response signal only when certain conditions are satisfied.
- Specific conditions may be that the antigen recognition unit recognizes the antigen.
- Certain conditions may be that the antigen recognition site forms a bond with the antigen.
- Specific conditions may be that the signal generated when the antigen recognition unit and the antigen form a bond.
- Specific conditions may be that the antigen recognition unit recognizes or binds the antigen and then separates it.
- the immune response signal may be a signal related to the growth and differentiation of immune cells.
- the immune response signal may be a signal associated with the death of immune cells.
- the immune response signal may be a signal related to the activity of immune cells.
- the immune response signal may be a signal associated with the assistance of the immune response.
- the immune response signal may be specifically activated by a signal generated by the antigen recognition unit.
- the immune response signal may be a signal that regulates expression of a target gene.
- the immune response signal may be a signal that suppresses the immune response.
- the signal generator may include an additional signal generator.
- Additional signal generator means a site that generates additional immune response signals to the immune response signals generated by the first and / or second signal generator as part of the artificial receptor.
- the additional signal generator is referred to as n-th signal generator (n ⁇ 1) in this order.
- the artificial receptor may include an additional signal generator in addition to the first signal generator.
- Two or more additional signal generators may be included in the artificial receptor.
- the additional signal generator may be a structure that generates 4-1BB, CD27, CD28, ICOS, OX40 or other immune response signal.
- the conditions under which the additional signal generator generates the immune response signal and the characteristics of the generated immune response signal include contents corresponding to the immune response signal of the first and / or second signal generator.
- the immune response signal may be to promote the synthesis of cytokines.
- the immune response signal may be to promote or inhibit the secretion of cytokines.
- the cytokine may be preferably IL-2, TNF ⁇ or IFN- ⁇ .
- the immune response signal may be a signal that helps growth or differentiation of other immune cells.
- Immune response signals may be signals that regulate the activity of other immune cells.
- the immune response signal may be a signal that attracts other immune cells to the location where the signal occurs.
- the present invention encompasses all possible binding relationships of artificial receptors.
- embodiments of the artificial receptor of the present invention are not limited to those mentioned herein.
- the artificial receptor may be comprised of an antigen recognition portion-receptor body portion-first signaling portion.
- the receptor body may optionally be included.
- the artificial receptor may be composed of an antigen recognition unit-receptor body portion-second signal generator-first signal generator.
- the receptor body may optionally be included. In this case, the positions of the first signal generator and the second signal generator may be changed.
- the artificial receptor may be composed of an antigen recognition unit-receptor body portion-second signal generator-third signal generator-first signal generator.
- the receptor body may optionally be included. In this case, the positions of the first signal generator to the third signal generator may be changed.
- the number of signal generators in the artificial receptor is not limited to one to three, but may be included in more than three.
- the artificial receptor may have a structure of an antigen recognition unit-signal generator-receptor body.
- the structure may be advantageous when it is necessary to generate an immune response signal that acts extracellularly with the artificial receptor.
- Co receptors may function corresponding to wild receptors.
- the artificial receptor may function to form a specific positional relationship by forming a bond with a specific antigen.
- Artificial receptors may function to recognize specific antigens and generate immune response signals that promote immune responses to specific antigens.
- Artificial receptors can function to suppress the immune response to cells in the body by recognizing antigens in general body cells.
- the artificial receptor may optionally include a signal sequence.
- the receptor may help the receptor to be easily located on the immune cell membrane.
- the receptor in the immune cell contains the signal sequence of the transmembrane protein, the receptor may help to pass through the membrane of the immune cell and position it on the outer membrane of the immune cell.
- the artificial receptor may comprise one or more signal sequences.
- the signal sequence may include many positively charged amino acids.
- the signal sequence may comprise a positively charged amino acid at a position near the N or C terminus.
- the signal sequence may be a signal sequence of the transmembrane protein.
- the signal sequence may be a signal sequence of a protein located on the outer membrane of an immune cell.
- the signal sequence may be included in the structure of the artificial receptor, that is, the antigen recognition unit, the receptor body, the first signal generator, and the additional signal generator.
- the signal sequence may be located near the N or C terminal of each structure.
- the distance from the N or C terminal may be about 100 amino acids.
- the cell may be modified to include a specific T cell receptor (TCR) gene.
- TCR T cell receptor
- the TCR is a tumor associated antigen (eg, melanoma antigen recognized by T cells 1), MAGEA3 (melanoma-associated antigen3), NY-ESOl, carcinoembryonic antigen (CEA), GP100, etc.
- NY-ES-Ol, melanoma may have binding specificity.
- the cell may be modified to include a specific chimeric antigen receptor (CAR).
- CAR is a tumor associated antigen (eg, CD 19, CD20, carbonic anhydrase IX (CAIX), CD 171, CEA, ERBB2, GD2, alpha-folate receptor, Lewis Y antigen, prostate specific membrane antigen (PSMA) Or tumor associated glycoprotein 72 (TAG72).
- a tumor associated antigen eg, CD 19, CD20, carbonic anhydrase IX (CAIX), CD 171, CEA, ERBB2, GD2, alpha-folate receptor, Lewis Y antigen, prostate specific membrane antigen (PSMA) Or tumor associated glycoprotein 72 (TAG72).
- PSMA prostate specific membrane antigen
- TAG72 tumor associated glycoprotein 72
- the cell may be modified to bind to one or more of the following tumor antigens, eg, by TCR or CAR.
- Tumor antigens include, but are not limited to, AD034, AKT1, BRAP, CAGE, CDX2, CLP, CT-7, CT8 / HOM-TES-85, cTAGE-1, EGFR, EGFRvIII, Fibulin-1, HAGE , HCA587 / MAGE-C2, hCAP-G, HCE661, HER2 / neu, HLA-Cw, HOM-HD-21 / Galectin9, HOM-MEEL-40 / SSX2, HOM-RCC-3.1.3 / CAXII, HOXA7, HOXB6 , Hu, HUB 1, KM-HN-3, KM-KN-1, KOC1, KOC2, KOC3, KOC3, LAGE-1, MAGE-1, MAGE-4a, MPPl 1, MSLN, NNP-1, NY-BR -1, NY-BR-62, NY-BR-85, NY-CO-37, NY-CO-38, NY-ESO-1, NY-ESO-5
- Antigen binding regulatory elements antigen binding regulating element
- the cells of the present invention may further comprise an "antigen binding regulatory element".
- an “antigen binding regulatory element” is an element that enables binding between a receptor and an antigen, and may be a gene or a protein that performs this function.
- HVGD host HVGD (graft disease)
- HostGraft in which an immune response to externally manipulated cells is activated and the therapeutic effect is lost.
- the antigen binding regulatory element may be a protein or gene related to the structure of the receptor.
- the antigen binding regulatory element may be a protein or gene homologous to the structure of the receptor.
- the antigen binding regulatory element may be dCK.
- the antigen binding regulatory element may be CD52.
- the antigen binding regulatory element may be B2M.
- An antigen binding regulatory element may be a protein or gene associated with a construct recognized by a receptor.
- the antigen binding regulatory element may be an MHC protein.
- One embodiment of the present invention is an immune cell comprising the artificially engineered immunoregulatory genes or proteins they express.
- the artificially engineered immunoregulatory genes or proteins they express And immune cells comprising receptors.
- Representative examples of the cells of the present invention are immune cells.
- the immune cells may include peripheral blood mononuclear cells (PBMCs), natural killer cells, NK cells, monocytes, T cells, CAR-T cells, macrophages, NKT cells ( Natural killer T cell) may be one or more selected from the group consisting of.
- PBMCs peripheral blood mononuclear cells
- natural killer cells NK cells
- monocytes T cells
- CAR-T cells CAR-T cells
- macrophages NK cells
- NKT cells Natural killer T cell
- the cells may be T cells, CAR-T cells, natural killer cells or natural killer T cells.
- T cells T cells
- NK cells NKT cells
- immune cell proliferation eg, limited proliferation of immune cells after adoptive delivery
- immune cell survival eg, induction of apoptosis of immune cells by a factor in the tumor environment
- immune cell function eg, cytotoxic immune cell function by inhibitors secreted by host immune cells and cancer cells.
- one or more immune cell expression genes for example one or more genes selected from the group consisting of PD-1, CTLA-4, TNFAIP3, DGKA, DGKZ, Fas, EGR2, PPP2R2D, PSGL-1, KDM6A, and TET2 Is inactivated and regulates these limiting factors through immune cells.
- one or more immune cell expression genes such as PD-1, CTLA-4, TNFAIP3, DGKA, DGKZ, Fas, EGR2, PPP2R2D, PSGL-1, KDM6A and / or TET2 genes are used to propagate one or more immune cells. Targeted and manipulated to knock out, knock down or knock in each independently to affect survival, function.
- DGKA and DGKZ were knocked out simultaneously.
- one or more immune cell expression genes such as PD-1, CTLA-4, TNFAIP3, DGKA, DGKZ, Fas, EGR2, PPP2R2D, PSGL-1, KDM6A and / or TET2 genes are non-coding or coding regions, Affecting the proliferation, survival, and function of one or more immune cells, for example by targeting promoter regions, enhancers, 3'UTRs, and / or polyadenylation signal sequences, or transcription sequences such as intron or exon sequences To be knocked out, knocked down or knocked-in independently.
- one or more immune cell expression genes such as PD-1, CTLA-4, TNFAIP3, DGKA, DGKZ, Fas, EGR2, PPP2R2D, PSGL-1, KDM6A and / or TET2 gene, are present at one or more sites in the sequence.
- the targets can be engineered to be knocked out, knocked down, or knocked down independently to affect the proliferation, survival, and function of one or more immune cells.
- another aspect of the present invention is the artificially engineered immunomodulatory element; And / or the immune system, which forms an immune response mechanism, to which cells comprising the same are involved.
- immune system of the present invention is a term that includes all the phenomena that affect the body's immune response by altering the function of artificially engineered immunoregulatory elements, ie, involved in mechanisms that exhibit new immune efficacy. It includes all materials, compositions, methods and uses that are directly or indirectly involved in such immune system. For example, all genes involved in innate, adaptive, cellular, humoral, active and passive immune responses, immune cells and immune organs / tissues are included.
- immune system factor Each of the elements that make up this immune system are collectively referred to as an "immune system factor.”
- the immune system of the present invention includes manipulated immune cells.
- Manipulated immune cells refer to immune cells that have been artificially manipulated rather than natural. Recently, techniques for enhancing immune efficacy by extracting immune cells from the body and applying artificial manipulations have been actively studied. Immune cells that have been manipulated in this way are excellent in their immune efficacy against certain diseases, and thus are being highlighted as new treatment methods. In particular, research on engineered immune cells has been actively conducted in connection with the treatment of cancer.
- the engineered immune cells may be functionally engineered immune cells or artificial structure-added immune cells.
- Engineered immune cells ( functionally manipulated immune cell )
- Wild-type immune cell of the present invention means that the wild-receptor or immunoregulatory element is engineered in nature as an immune cell.
- immune cells include not only immune cells that have already differentiated but also cells before differentiation (e.g., stem cells).
- the engineered immune cells may be immune cells engineered with wild receptors.
- the wild receptor may be TCR.
- the engineered immune cell may be one in which the wild receptor is absent or present in lesser proportions.
- the engineered immune cells may be ones in which the wild receptors are present in more proportions on the surface.
- the engineered immune cells may be enhanced in the ability of wild receptors to recognize specific antigens.
- the engineered immune cells may be immune cells engineered with immunoregulatory elements.
- Functionally engineered immune cells may be engineered immune cell activity regulatory elements.
- the functional immune cells may be immune cells in which one or more selected from SHP-1, PD-1, CTLA-4, CBLB, ILT-2, KIR2DL4, and PSGL-1 are inactivated.
- Functionally engineered immune cells may be engineered immune cell growth regulators.
- the functional immune cells may be immune cells in which at least one selected from DGK-alpha, DGK-zeta, Fas, EGR2, Egr3, PPP2R2D, and A20 is inactivated.
- a preferred embodiment is to inactivate one or more selected from DGK-alpha, DGK-zeta, EGR2, PPP2R2D, A20.
- Functionally engineered immune cells may be engineered immune cell death regulatory elements.
- the functional immune cells may be immune cells in which at least one selected from Daxx, Bim, Bid, BAD, PD-1, and CTLA-4 is inactivated.
- the engineered immune cells may be immune cells inserted elements that induce self-killing.
- Functionally engineered immune cells may have been engineered immune cell loss factor.
- the functional immune cells may be immune cells in which one or more selected from TET2 and Wnt Akt are inactivated.
- Functionally engineered immune cells may be engineered cytokine secretion elements.
- Functionally engineered immune cells may be engineered antigen binding regulatory elements.
- the functional immune cells may be immune cells in which at least one selected from among dCK, CD52, B2M, and MHC is inactivated.
- the engineered immune cells may be engineered with immunoregulatory elements other than those mentioned above.
- Functionally engineered immune cells may be one or more immunomodulatory elements are manipulated simultaneously. At this time, one or more kinds of immunoregulatory elements may be manipulated.
- one immunomodulatory element when one immunomodulatory element is manipulated, one kind of new immune effect does not have to appear. Manipulation of one immunoregulatory element may result in or inhibit several new immune effects.
- the new immunopotency may be a controlled ability to recognize specific antigens.
- the new immunopotency may be an improved ability to recognize specific antigens.
- the specific antigen may be an antigen of a disease.
- it may be an antigen of cancer cells.
- the new immunopotency may be a decrease in the ability to recognize certain antigens.
- the new immune efficacy may be an improved immune capacity.
- the new immune effect may be that of the growth of immune cells.
- the immune effect may be to promote or alleviate the growth and differentiation of immune cells.
- the new immunopotency may be a controlled killing of immune cells.
- the immune effect may be to prevent the death of immune cells.
- the immune efficacy may be to allow the immune cells to die on their own after a suitable time.
- the new immunopotential may be one in which immune cells lose their function.
- the new immunopotential may be a regulated cytokine secretion of immune cells.
- the immune effect may be to promote or inhibit the secretion of cytokines.
- the new immunopotency may be to modulate the antigen binding capacity of the wild receptor in immune cells.
- the immunogenic effect may be to improve the specificity of the wild receptor for a specific antigen.
- Immunomedianic immune cell refers to the addition of artificial structures in immune cells.
- the prosthetic immune cells may be immune cells to which an artificial receptor has been added.
- the artificial receptor may be capable of recognizing antigens of certain diseases.
- the structure-added immune cells may be CAR-T cells.
- each artificial receptor may be one that is expressed in time series according to the conditions.
- the first artificial receptor may generate an immune response signal that initiates the expression of the second artificial receptor gene, and then the second artificial receptor may be expressed.
- the second artificial receptor may produce an immune response signal that induces an immune response against cancer cells.
- the cancer cell attack ability of the engineered immune cells can be improved.
- Artificial receptors may be capable of recognizing engineered immune cells.
- Artificial receptors may be capable of recognizing general body cells.
- the structure-added immune cells may be iCAR-T cells.
- the artificial receptor may be capable of recognizing a third substance.
- the third substance may have the ability to bind to the antigen of a specific disease.
- the third substance may bind to the artificial receptor and at the same time may bind to the antigen of a specific disease.
- it may have the ability to bind to cancer cell antigens simultaneously with the artificial receptor.
- the artificial structure-added immune cell may be an immune cell added with an artificial structure having a specific function, in addition to the artificial receptor.
- artificial immune cells When artificial immune structures are added to immune cells, artificial immune cells may have new immune effects.
- the new immunopotency may be to bind specific antigens so that immune cells are in a specific positional relationship with the antigen.
- the new immune potency may be a function of recognizing a specific antigen and promoting an immune response against the specific antigen.
- the new immunopotency may be a function of suppressing excessive immune responses.
- the new immunopotency may be a function of regulating the pathway of the immune response.
- the new immune effect may be a function of forming a bond with a third substance to identify a specific disease.
- the third material may be a biomarker of a specific disease.
- One preferred example of the specific antigens mentioned above may be antigens of cancer cells.
- Antigens of cancer cells include, but are not limited to, AD034, AKT1, BRAP, CAGE, CDX2, CLP, CT-7, CT8 / HOM-TES-85, cTAGE-1, EGFR, EGFRvIII, Fibulin-1, HAGE, HCA587 / MAGE-C2, hCAP-G, HCE661, HER2 / neu, HLA-Cw, HOM-HD-21 / Galectin9, HOM-MEEL-40 / SSX2, HOM-RCC-3.1.3 / CAXII, HOXA7, HOXB6, Hu, HUB 1, KM-HN-3, KM-KN-1, KOC1, KOC2, KOC3, KOC3, LAGE-1, MAGE-1, MAGE-4a, MPPl 1, MSLN, NNP-1, NY-BR-1, NY-BR-62, NY-BR-85, NY-CO-37, NY-CO-38, NY-ESO-1, NY-ESO-5, NY-
- Combination type immune cells ( hybrid manipulated immune cell )
- a “complex operated immune cell” refers to a cell in which both immunomodulatory elements and artificial structures are added as immune cells.
- Manipulation of immunoregulatory elements in multimodal immune cells is as described for functionally engineered immune cells.
- the addition of the artificial structure is as described for the artificial structure-added immune cells.
- the position where the artificial structure is added may be the same as the position of the gene where the manipulation took place.
- the new immunological efficacy of the hybridized immune cells may include new immune effects of the functionally engineered immune cells and the artificial structure-added immune cells, and may be further improved by the interaction between them.
- Improved immune efficacy may be to improve the specificity and immune response to a particular disease.
- the multi-engineered immune cell may be one that has enhanced specificity and immune response to cancer.
- the immune system of the present invention comprises a desired immune response and thereby a disease treatment mechanism made by an engineered immunoregulatory element and / or a manipulated immune cell.
- it may be used to influence immune cell proliferation using immunoregulatory elements and / or engineered immune cells that inactivate genes that inhibit immune cell proliferation.
- it may be used to influence immune cell survival using immunoregulatory elements and / or engineered immune cells that inactivate genes that mediate immune cell apoptosis.
- it may be used to influence immune cell function using immunoregulatory elements and / or engineered immune cells that have inactivated genes encoding immunosuppressive and inhibitory signaling factors.
- compositions discussed herein affect one or more of the factors that limit the efficacy of genetically modified immune cells as therapeutic agents for a particular disease, such as immune cell proliferation, immune cell survival, immune cell function, or any combination thereof. It can be used individually or in combination to drive.
- immuno-regulating therapy refers to the treatment of diseases by controlling the immune response in the body by using an engineered immunoregulatory element and / or engineered immune cells.
- diseases can be treated by activating or inactivating an immune response in the body using immune cells such as dendritic cells, natural killer cells, and T cells.
- immune cells such as dendritic cells, natural killer cells, and T cells.
- immunomodulatory therapies are mainly developed as an indication for cancer treatment, and by directly injecting immune cells to the patient to activate immune function, and thus obtain a therapeutic effect, the immunomodulatory therapy is different from the conventional surgery, chemotherapy or radiation therapy used in cancer treatment. It is a different therapeutic mechanism.
- immunomodulatory therapy includes dendritic immunomodulatory cell therapies, lymphokine activated cells (LAKs), tumor infiltrating T cells (tumor), depending on the immune cells used and the genes introduced into the cells in the manufacturing process.
- LAKs lymphokine activated cells
- tumor infiltrating T cells tumor infiltrating T cells
- TIL T lymphocytle
- TCR-T T cell receptor-modified T cells
- CAR-T chimeric antigen receptor-modified T cells
- the manipulation or modification of the immunomodulatory elements, immune cells, and substances involved in the immune system of the present invention may be accomplished, preferably through genetic manipulation.
- compositions and methods can be provided that target and genetically engineer some or all of the non-coding or coding regions of an immunoregulatory gene that affect the proliferation, survival and / or function of immune cells.
- one or more of the immunoregulatory genes involved therein can be engineered or modified for formation of a desired immune system. This can be done through modification of the nucleic acids that make up the gene. As a result of the operation, knock down, knock out, and knock in forms are all included.
- a promoter region, or transcriptional sequence, such as an intron or exon sequence can be targeted.
- Coding sequences, such as coding regions, initial coding regions, can be targeted for alteration and knockout of expression.
- the nucleic acid modification is one or more nucleotides, such as 1 to 30 bp, 1 to 27 bp, 1 to 25 bp, 1 to 23 bp, 1 to 20 bp, 1 to 15 bp, 1 to 10 bp, 1 to 5 bp, 1 to 3 bp, or Substitution, deletion, and / or insertion of 1 bp of nucleotides.
- a deletion in one or more of the immunoregulatory genes to knock out one or more of the immunoregulatory genes, or to eliminate one or more expressions, or to knock out one or more one or two alleles Or targeted to include mutations.
- gene knockdown can be used to reduce expression of unwanted alleles or transcripts.
- it can be used to alter immunoregulatory genes that affect immune cell function by targeting non-coding sequences of promoters, enhancers, introns, 3'UTRs, and / or polyadenylation signals.
- said gene nucleic acid alteration may result in the regulation of activity, such as activation or inactivation of an immunoregulatory gene.
- said genetic nucleic acid modification may be to inactivate the targeted gene by catalyzing single stranded or double stranded cleavage, i.e., nucleic acid strand damage, of a specific site within the gene targeted by the guide nucleic acid-editor protein complex.
- nucleic acid strand breaks can be repaired through mechanisms such as homologous recombination or nonhomologous end joining (NHEJ).
- NHEJ nonhomologous end joining
- the invention may provide said genetically engineered site.
- an NHEJ-mediated alteration refers to a position within said gene that results in a reduction or elimination of the expression of an immunoregulatory gene product.
- the genetic manipulation may be performed in consideration of a gene expression control process.
- RNA processing regulation RNA processing regulation
- RNA transport regulation RNA degradation regulation
- translation regulation protein modification regulation step
- RNAi RNA interference or RNA silencing
- sRNAs small RNAs
- Expression can be controlled.
- nucleic acid-editor protein complexes capable of catalyzing the hydrolysis (cleavage) of bonds between nucleic acids in DNA or RNA molecules, preferably DNA molecules.
- Guide nucleic acid-editor protein complexes can be used.
- At least one nuclease selected from the group consisting of meganuclease, zinc finger nuclease, CRISPR / Cas9 (Cas9 protein), CRISPR-Cpf1 (Cpf1 protein), and TALE-nuclease.
- Genes can be manipulated using clease to control the expression of genetic information.
- Preferred examples include, but are not limited to, non-homologous end joining (NHEJ) or homologous recombination repair using a guide nucleic acid-editor protein complex, for example, using a CRISPR / Cas system. homology-directed repair (HDR).
- NHEJ non-homologous end joining
- HDR homology-directed repair
- immunomodulatory genes that affect the proliferation, survival and / or function of immune cells include PD-1 gene, CTLA-4 gene, TNFAIP3 gene, DGKA gene, DGKZ gene, Fas gene, EGR2 gene, PPP2R2D gene. , TET2 gene, PSGL-1 gene and KDM6A gene.
- Target sequence sites of the genes that is, sites where nucleic acid modification can occur are summarized in Table 1 below (with the target sequence sites described in Table 1 including PAM sequence 5′-NGG-3 ′ at the 3 ′ end). Listed)
- the said target sequence can target two or more types simultaneously.
- the said gene can target 2 or more types simultaneously.
- Two or more target sequences in the homologous gene or two or more target sequences in the heterologous gene can be targeted simultaneously.
- DGKa or DGKz may be targeted, respectively.
- DGKa and DGKz may be simultaneously targeted.
- Guide nucleic acid-editor protein complex means a complex formed through the interaction of a guide nucleic acid and an editor protein, and the nucleic acid-protein complex includes a guide nucleic acid and an editor protein.
- guide nucleic acid refers to a nucleic acid capable of recognizing a target nucleic acid, gene, chromosome or protein.
- the guide nucleic acid may be in the form of DNA, RNA or DNA / RNA mixture, and may have 5 to 150 nucleic acid sequences.
- the guide nucleic acid may comprise one or more domains.
- the domain may be a guide domain, a first complementary domain, a connecting domain, a second complementary domain, a proximal domain, a tail domain, or the like, but is not limited thereto.
- the guide nucleic acid may include two or more domains, and may include the same domain repeatedly or include different domains.
- the guide nucleic acid may be one continuous nucleic acid sequence.
- one contiguous nucleic acid sequence may be (N) m, where N is A, T, C or G, or A, U, C or G, and m means an integer from 1 to 150 .
- the guide nucleic acid may be two or more consecutive nucleic acid sequences.
- two or more consecutive nucleic acid sequences may be (N) m and (N) o, where N is A, T, C or G, or A, U, C or G, and m and o are It means an integer of 1 to 150, m and o may be the same or different from each other.
- editor protein refers to a peptide, polypeptide or protein that can bind directly to a nucleic acid or not, but not directly.
- the editor protein may also be conceptually referred to as “genetic scissors” or RGEN (RNA-Guided Endonuclease).
- the editor protein may be an enzyme.
- the editor protein may be a fusion protein.
- fusion protein refers to a protein produced by fusing an enzyme and an additional domain, peptide, polypeptide or protein.
- enzyme refers to a protein including a domain capable of cleaving a nucleic acid, gene, chromosome or protein.
- the additional domain, peptide, polypeptide or protein may be a functional domain, peptide, polypeptide or protein having the same or different function as the enzyme.
- the fusion protein is at or near the amino terminus of the enzyme; At or near the carboxy terminus; Middle part of an enzyme; Or may comprise additional domains, peptides, polypeptides or proteins in one or more of these combinations.
- the fusion protein is at or near the amino terminus of the enzyme; At or near the carboxy terminus; Middle part of an enzyme; Or one or more of these combinations may comprise a functional domain, peptide, polypeptide or protein.
- Guide nucleic acid-editor protein complexes can modify a subject.
- the subject may be a target nucleic acid, gene, chromosome or protein.
- the guide nucleic acid-editor protein complex may ultimately regulate (eg, inhibit, inhibit, decrease, increase or promote) expression of a target protein, or may remove or express a new protein. To be able.
- the guide nucleic acid-editor protein complex may act at the DNA, RNA, gene or chromosome level.
- the guide nucleic acid-editor protein complex may act at the stage of transcription and translation of the gene.
- the guide nucleic acid-editor protein complex may act at the protein level.
- Guide nucleic acids are nucleic acids capable of recognizing target nucleic acids, genes, chromosomes or proteins, forming guide nucleic acid-protein complexes.
- the guide nucleic acid serves to recognize or target the nucleic acid, gene, chromosome or protein to which the guide nucleic acid-protein complex is targeted.
- the guide nucleic acid may be in the form of DNA, RNA or DNA / RNA mixture, and may have 5 to 150 nucleic acid sequences.
- the guide nucleic acid may be linear or circular.
- the guide nucleic acid may be one continuous nucleic acid sequence.
- one contiguous nucleic acid sequence may be (N) m, where N is A, T, C or G, or A, U, C or G, and m means an integer from 1 to 150 .
- the guide nucleic acid may be two or more consecutive nucleic acid sequences.
- two or more consecutive nucleic acid sequences may be (N) m and (N) o, where N is A, T, C or G, or A, U, C or G, and m and o are It means an integer of 1 to 150, m and o may be the same or different from each other.
- the guide nucleic acid may comprise one or more domains.
- the domain may be a guide domain, a first complementary domain, a connecting domain, a second complementary domain, a proximal domain, a tail domain, and the like, but is not limited thereto.
- the guide nucleic acid may include two or more domains, and may include the same domain repeatedly or include different domains.
- a “guide domain” is a domain containing complementary guide sequences capable of complementary binding to a target sequence on a target gene or nucleic acid, and serves for specific interaction with the target gene or nucleic acid.
- the guide sequence is a nucleic acid sequence that is complementary to the target sequence on the target gene or nucleic acid, for example at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95 It may be at least% complementary or completely complementary nucleic acid sequence.
- the guide domain may be 5 to 50 base sequences.
- the guide domain is 5 to 50 base sequences, 10 to 50 base sequences, 15 to 50 base sequences, 20 to 50 base sequences, 25 to 50 base sequences, 30 to 50 base sequences, 35 To 50 nucleotide sequences, 40 to 50 nucleotide sequences, or 45 to 50 nucleotide sequences.
- the guide domain includes 1 to 5 base sequences, 5 to 10 base sequences, 10 to 15 base sequences, 15 to 20 base sequences, 20 to 25 base sequences, 25 to 30 base sequences, It may be 30 to 35 base sequences, 35 to 40 base sequences, 40 to 45 base sequences or 45 to 50 base sequences.
- the guide domain may comprise a guide sequence.
- the guide sequence may be a complementary base sequence capable of complementary binding to the target sequence on the target gene or nucleic acid.
- the guide sequence may be a nucleic acid sequence that is complementary to the target sequence on the target gene or nucleic acid, for example at least 70%, 75%, 80%, 85%, 90% or 95% or more complementary or completely complementary. Nucleic acid sequence.
- the guide sequence may be 5 to 50 nucleotide sequences.
- the guide domain is 5 to 50 base sequences, 10 to 50 base sequences, 15 to 50 base sequences, 20 to 50 base sequences, 25 to 50 base sequences, 30 to 50 base sequences, 35 To 50 nucleotide sequences, 40 to 50 nucleotide sequences, or 45 to 50 nucleotide sequences.
- the guide sequence is 1 to 5 base sequences, 5 to 10 base sequences, 10 to 15 base sequences, 15 to 20 base sequences, 20 to 25 base sequences, 25 to 30 base sequences, It may be 30 to 35 base sequences, 35 to 40 base sequences, 40 to 45 base sequences or 45 to 50 base sequences.
- the guide domain may include a guide sequence and an additional nucleotide sequence.
- the additional base sequence may be for improving or decreasing the function of the guide domain.
- the additional base sequence may be for improving or decreasing the function of the guide sequence.
- the additional base sequence may be 1 to 35 base sequences.
- the additional base sequence may be 5 to 35 base sequences, 10 to 35 base sequences, 15 to 35 base sequences, 20 to 35 base sequences, 25 to 35 base sequences, or 30 to 35 base sequences. Can be.
- the additional base sequence is 1 to 5 base sequences, 5 to 10 base sequences, 10 to 15 base sequences, 15 to 20 base sequences, 20 to 25 base sequences, 25 to 30 base sequences Or 30 to 35 base sequences.
- the additional base sequence may be located at the 5 'end of the guide sequence.
- the additional base sequence may be located at the 3 'end of the guide sequence.
- a “first complementary domain” is a nucleic acid sequence comprising a complementary nucleic acid sequence and a second complementary domain, and is complementary enough to form a double strand with the second complementary domain.
- the first complementary domain may be 5 to 35 base sequences.
- the first complementary domain may be 5 to 35 nucleotide sequences, 10 to 35 nucleotide sequences, 15 to 35 nucleotide sequences, 20 to 35 nucleotide sequences, 25 to 35 nucleotide sequences, or 30 to 35 nucleotide sequences. Can be.
- the first complementary domain includes 1 to 5 nucleotide sequences, 5 to 10 nucleotide sequences, 10 to 15 nucleotide sequences, 15 to 20 nucleotide sequences, 20 to 25 nucleotide sequences, 25 to 30 It can be a base sequence or 30 to 35 base sequences.
- a “linking domain” is a nucleic acid sequence that connects two or more domains, wherein the linking domain connects two or more domains that are the same or different.
- the linking domain may be covalently or non-covalently linked to two or more domains, or may connect two or more domains covalently or non-covalently.
- the linking domain may be 1 to 30 nucleotide sequences.
- the linking domain may be 1 to 5 nucleotide sequences, 5 to 10 nucleotide sequences, 10 to 15 nucleotide sequences, 15 to 20 nucleotide sequences, 20 to 25 nucleotide sequences, or 25 to 30 nucleotide sequences. Can be.
- the linking domain may include 1 to 30 nucleotide sequences, 5 to 30 nucleotide sequences, 10 to 30 nucleotide sequences, 15 to 30 nucleotide sequences, 20 to 30 nucleotide sequences, or 25 to 30 nucleotide sequences. Can be.
- a “second complementary domain” is a nucleic acid sequence comprising a complementary nucleic acid sequence with a first complementary domain, and has a complementarity enough to form a double strand with the first complementary domain.
- the second complementary domain includes a complementary base sequence with the first complementary domain and a base sequence without complementarity with the first complementary domain, eg, a base sequence that does not form a double strand with the first complementary domain.
- the base sequence may be longer than the first complementary domain.
- the second complementary domain may be 5 to 35 base sequences.
- the second complementary domain may include 1 to 35 base sequences, 5 to 35 base sequences, 10 to 35 base sequences, 15 to 35 base sequences, 20 to 35 base sequences, and 25 to 35 bases. Sequence or 30 to 35 nucleotide sequences.
- the second complementary domain includes 1 to 5 nucleotide sequences, 5 to 10 nucleotide sequences, 10 to 15 nucleotide sequences, 15 to 20 nucleotide sequences, 20 to 25 nucleotide sequences, and 25 to 30 nucleotide sequences. Base sequence or 30 to 35 base sequences.
- proximal domain is a nucleic acid sequence located proximate to the second complementary domain.
- the proximal domain may comprise complementary nucleotide sequences within the proximal domain and may form double strands by the complementary nucleotide sequences.
- the proximal domain may be 1 to 20 nucleotide sequences.
- the proximal domain may be 1 to 20 nucleotide sequences, 5 to 20 nucleotide sequences, 10 to 20 nucleotide sequences, or 15 to 20 nucleotide sequences.
- the proximal domain may be 1 to 5 base sequences, 5 to 10 base sequences, 10 to 15 base sequences, or 15 to 20 base sequences.
- the “tail domain” is a nucleic acid sequence located at one or more ends of both ends of the guide nucleic acid.
- the tail domain may comprise complementary sequences within the tail domain, and may form double strands by complementary sequences.
- the tail domain may be 1 to 50 nucleotide sequences.
- the tail domain is 5 to 50 base sequences, 10 to 50 base sequences, 15 to 50 base sequences, 20 to 50 base sequences, 25 to 50 base sequences, 30 to 50 base sequences, 35 To 50 nucleotide sequences, 40 to 50 nucleotide sequences, or 45 to 50 nucleotide sequences.
- the tail domain may include 1 to 5 base sequences, 5 to 10 base sequences, 10 to 15 base sequences, 15 to 20 base sequences, 20 to 25 base sequences, 25 to 30 base sequences, It may be 30 to 35 base sequences, 35 to 40 base sequences, 40 to 45 base sequences or 45 to 50 base sequences.
- nucleic acid sequences included in the domains may include selective or additional chemical modification. have.
- the chemical modification may be methylation, acetylation, phosphorylation, phosphorothioate linkage, locked nucleic acid (LNA), 2'-O-methyl 3'phosphorothioate (MS) or 2'-O-methyl 3'thioPACE (MSP). It is not limited.
- Guide nucleic acids include one or more domains.
- the guide nucleic acid may include a guide domain.
- the guide nucleic acid may comprise a first complementary domain.
- the guide nucleic acid may comprise a linking domain.
- the guide nucleic acid may comprise a second complementary domain.
- the guide nucleic acid may comprise a proximal domain.
- the guide nucleic acid may comprise a tail domain.
- the number of domains may be 1, 2, 3, 4, 5, 6 or more.
- the guide nucleic acid may include 1, 2, 3, 4, 5, 6 or more guide domains.
- the guide nucleic acid may comprise one, two, three, four, five, six or more first complementary domains.
- the guide nucleic acid may comprise 1, 2, 3, 4, 5, 6 or more linking domains.
- the guide nucleic acid may comprise one, two, three, four, five, six or more second complementary domains.
- the guide nucleic acid may comprise 1, 2, 3, 4, 5, 6 or more proximal domains.
- the guide nucleic acid may comprise 1, 2, 3, 4, 5, 6 or more tail domains.
- the guide nucleic acid may be included by overlapping one domain.
- the guide nucleic acid may be included without overlapping or overlapping multiple domains.
- the guide nucleic acid may include the same kind of domain, wherein the same kind of domain may have the same nucleic acid sequence or different nucleic acid sequences.
- the guide nucleic acid may include two kinds of domains, wherein the other two kinds of domains may have different nucleic acid sequences or the same nucleic acid sequences.
- the guide nucleic acid may include three kinds of domains, wherein the other three kinds of domains may have different nucleic acid sequences or the same nucleic acid sequences.
- the guide nucleic acid may include four kinds of domains, wherein the other four kinds of domains may have different nucleic acid sequences or the same nucleic acid sequences.
- the guide nucleic acid may include five kinds of domains, wherein the other five kinds of domains may have different nucleic acid sequences or the same nucleic acid sequences.
- the guide nucleic acid may include six kinds of domains, wherein the other six kinds of domains may have different nucleic acid sequences or the same nucleic acid sequences.
- the guide nucleic acid is [guide domain]-[first complementary domain]-[linking domain]-[second complementary domain]-[linking domain]-[guide domain]-[first complementary domain] -[Linking domain]-[second complementary domain], wherein the two guide domains may comprise guide sequences for different or identical targets, and the two first complementary domains Two second complementary domains may have the same nucleic acid sequence or different nucleic acid sequences.
- the guide domains contain guide sequences for different targets, the guide nucleic acids can specifically bind to two targets, where specific binding can occur simultaneously or sequentially.
- the linking domain may be cleaved by a specific enzyme, and in the presence of a specific enzyme, the guide nucleic acid may be divided into two parts or three parts.
- gRNA As an embodiment of the guide nucleic acid of the present invention, gRNA is described below.
- GRNA refers to a gRNA-CRISPR enzyme complex, ie, a specific targeting nucleic acid of a CRISPR complex, to a target gene or nucleic acid.
- the gRNA refers to a target gene or nucleic acid specific RNA, and can bind to the CRISPR enzyme to direct the CRISPR enzyme to the target gene or nucleic acid.
- the gRNA may comprise a plurality of domains. Each domain allows for intra- or inter-strand interaction of three-dimensional behavior or active forms of gRNAs.
- gRNAs include single-stranded gRNAs (single RNA molecules); Or double gRNA (comprising more than one typically two separate RNA molecules).
- the single stranded gRNA comprises a guide domain in the 5 'to 3' direction, ie, a domain comprising a guide sequence capable of complementary binding to a target gene or nucleic acid; A first complementary domain; Connecting domains; A second complementary domain, a domain having a sequence complementary to the first complementary domain sequence and thus capable of forming a double stranded nucleic acid with the first complementary domain; Proximal domain; And optionally a tail domain.
- the dual gRNA comprises a guide domain from the 5 'to 3' direction, ie a domain comprising a guide sequence capable of complementary binding to a target gene or nucleic acid and a first complementary domain.
- the first strand and a second complementary domain, a domain having a sequence complementary to the first complementary domain sequence, capable of forming a double stranded nucleic acid with the first complementary domain, and a proximal domain; And optionally a second strand comprising a tail domain.
- the first strand may be referred to as crRNA
- the second strand may be referred to as tracrRNA.
- the crRNA may comprise a guide domain and a first complementary domain
- the tracrRNA may comprise a second complementary domain, a proximal domain and optionally a tail domain.
- the single stranded gRNA comprises a guide domain in the 3 'to 5' direction, ie, a domain comprising a guide sequence capable of complementary binding to a target gene or nucleic acid; A first complementary domain; And a second complementary domain having a sequence complementary to the first complementary domain sequence and thus capable of forming a double stranded nucleic acid with the first complementary domain.
- the guide domain comprises a complementary guide sequence capable of complementary binding to the target sequence on the target gene or nucleic acid.
- the guide sequence is a nucleic acid sequence that is complementary to the target sequence on the target gene or nucleic acid, for example at least 70%, 75%, 80%, 85%, 90% or 95% or more complementary or completely complementary nucleic acid sequence. Can be.
- the guide domain is believed to play a role in specific interactions with the target gene or nucleic acid of the gRNA-Cas complex, ie the CRISPR complex.
- the guide domain may be 5 to 50 base sequences.
- the guide domain has 16 nucleotide sequences, 17 nucleotide sequences, 18 nucleotide sequences, 19 nucleotide sequences, 20 nucleotide sequences, 21 nucleotide sequences, 22 nucleotide sequences, 23 nucleotide sequences, 24 It can be a base sequence or 25 base sequences.
- the guide domain comprises 16 base sequences, 17 base sequences, 18 base sequences, 19 base sequences, 20 base sequences, 21 base sequences, 22 base sequences, 23 base sequences, It may include 24 base sequences or 25 base sequences.
- the guide domain may include a guide sequence.
- the guide sequence may be a complementary base sequence capable of complementary binding to the target sequence on the target gene or nucleic acid.
- the guide sequence may be a nucleic acid sequence that is complementary to the target sequence on the target gene or nucleic acid, for example at least 70%, 75%, 80%, 85%, 90% or 95% or more complementary or completely complementary. Nucleic acid sequence.
- the guide sequence may be 5 to 50 nucleotide sequences.
- the guide sequence is 16 bases, 17 bases, 18 bases, 19 bases, 20 bases, 21 bases, 22 bases, 23 bases, 24 It can be a base sequence or 25 base sequences.
- the guide sequence comprises 16 base sequences, 17 base sequences, 18 base sequences, 19 base sequences, 20 base sequences, 21 base sequences, 22 base sequences, 23 base sequences, It may include 24 base sequences or 25 base sequences.
- the guide domain may include a guide sequence and an additional nucleotide sequence.
- the additional base sequence may be 1 to 35 base sequences.
- the additional base sequence is 1 base sequence, 2 base sequences, 3 base sequences, 4 base sequences, 5 base sequences, 6 base sequences, 7 base sequences, 8 base sequences, It may be 9 nucleotide sequences or 10 nucleotide sequences.
- the additional base sequence may be one base sequence G (guanine), or may be two base sequences GG.
- the additional base sequence may be located at the 5 'end of the guide sequence.
- the additional base sequence may be located at the 3 'end of the guide sequence.
- some or all of the base sequences of the guide domains may include chemical modifications.
- the chemical modification may be methylation, acetylation, phosphorylation, phosphorothioate linkage, locked nucleic acid (LNA), 2'-O-methyl 3'phosphorothioate (MS) or 2'-O-methyl 3'thioPACE (MSP). It is not limited.
- the first complementary domain comprises a complementary nucleic acid sequence with a second complementary domain, and is complementary enough to form a double strand with the second complementary domain.
- the first complementary domain may be 5 to 35 base sequences.
- the first complementary domain may include 5 to 35 base sequences.
- the first complementary domain is 5 base sequence, 6 base sequence, 7 base sequence, 8 base sequence, 9 base sequence, 10 base sequence, 11 base sequence, 12 base Sequence, 13 bases, 14 bases, 15 bases, 16 bases, 17 bases, 18 bases, 19 bases, 20 bases, 21 bases, 22 bases Sequence, 23 nucleotide sequences, 24 nucleotide sequences, or 25 nucleotide sequences.
- the first complementary domain includes 5 base sequences, 6 base sequences, 7 base sequences, 8 base sequences, 9 base sequences, 10 base sequences, 11 base sequences, and 12 base sequences.
- the first complementary domain may have homology with a naturally occurring first complementary domain or may be derived from a naturally occurring first complementary domain.
- the first complementary domain may have a difference in the nucleotide sequence of the first complementary domain according to a species present in nature, may be derived from a first complementary domain including a species present in nature, or It may have some or complete homology with the first complementary domain comprising the species present in nature.
- the first complementary domain is Streptococcus pyogenes, Campylobacter jejuni, Streptococcus thermophilus, Streptococcus aureus ) Or a first complementary domain or derived first complementary domain of Neisseria meningitides, at least 50% or at least homologous.
- the first complementary domain when the first complementary domain is a first complementary domain of Streptococcus pyogenes or a first complementary domain derived from Streptococcus pyogenes, the first complementary domain is 5′-GUUUUAGAGCUA-3 Or may be a sequence having at least 50% or more homology with 5′-GUUUUAGAGCUA-3 ′.
- the first complementary domain may further include (X) n, that is, 5′-GUUUUAGAGCUA (X) n-3 ′.
- X may be selected from the group consisting of bases A, T, U, and G, wherein n is the number of base sequences, and may be an integer of 5 to 15.
- (X) n may be repeated as many as n integers of the same base sequence, or may be an integer number of n base sequences in which bases A, T, U and G are mixed.
- the first complementary domain when the first complementary domain is a first complementary domain of Campylobacter jejuni or a first complementary domain derived from Campylobacter jejuni, the first complementary domain is 5'-GUUUUAGUCCCUUUUUAAAUUUCUUU. It may be -3 ', or may be a nucleotide sequence having at least 50% or more homology with 5'-GUUUUAGUCCCUUUUUAAAUUUCUU-3'. In this case, the first complementary domain may further include (X) n, that is, 5′-GUUUUAGUCCCUUUUUAAAUUUCUU (X) n-3 ′.
- X may be selected from the group consisting of bases A, T, U, and G, wherein n is the number of base sequences, and may be an integer of 5 to 15. In this case, (X) n may be repeated as many as n integers of the same base sequence, or may be an integer number of n base sequences in which bases A, T, U and G are mixed.
- the first complementary domain is Parcubacteria bacterium (GWC2011_GWC2_44_17), Lachnospiraceae bacterium (MC2017), Butyrivibrio proteoclascus (Butyrivibcus proteoclas , Peregrinibacteria bacterium (GW2011_GWA_33_10), Acidaminococcus sp. ), Porphyromonas crevioricanis, Prevotella disiens, Moraxella bovoculi (237), Smiihella sp.
- the first complementary domain when the first complementary domain is a first complementary domain of a Falcobacteria bacterium or a first complementary domain derived from Falcubacteria bacterium, the first complementary domain is 5′-UUUGUAGAU-3 ′ days. Or a nucleotide sequence having at least 50% or more homology with 5′-UUUGUAGAU-3 ′.
- the first complementary domain may further include (X) n, that is, 5 ′-(X) nUUUGUAGAU-3 ′.
- X may be selected from the group consisting of bases A, T, U and G, and n may be an integer of 1 to 5 as the number of base sequences.
- (X) n may be repeated as many as n integers of the same base sequence, or may be an integer number of n base sequences in which bases A, T, U and G are mixed.
- part or all of the base sequence of the first complementary domain may comprise a chemical modification.
- the chemical modification may be methylation, acetylation, phosphorylation, phosphorothioate linkage, locked nucleic acid (LNA), 2'-O-methyl 3'phosphorothioate (MS) or 2'-O-methyl 3'thioPACE (MSP). It is not limited.
- Linking domains are nucleic acid sequences that link two or more domains, and linking domains link two or more domains that are the same or different.
- the linking domain may be covalently or non-covalently linked to two or more domains, or may connect two or more domains covalently or non-covalently.
- the linking domain may be a nucleic acid sequence that connects the first and second complementary domains to generate a single stranded gRNA.
- the linking domain may be covalently or non-covalently bonded to the first and second complementary domains.
- the linking domain may connect the first and second complementary domains covalently or non-covalently.
- the linking domain may be 1 to 30 nucleotide sequences.
- the linking domain may include 1 to 30 nucleotide sequences.
- the linking domain comprises 1 to 5 base sequences, 5 to 10 base sequences, 10 to 15 base sequences, 15 to 20 base sequences, 20 to 25 base sequences, or 25 to 30 base sequences. Can be.
- the linking domain is 1 to 5 base sequences, 5 to 10 base sequences, 10 to 15 base sequences, 15 to 20 base sequences, 20 to 25 base sequences, or 25 to 30 bases. Sequences may be included.
- the linking domain is suitable for use in single-stranded gRNA molecules and can be covalently or non-covalently linked to the first and second strands of a double gRNA, or covalently or non-covalently linked to the first and second strands.
- Single stranded gRNAs can be used to generate.
- the linking domain may be used to generate single-stranded gRNAs either covalently or non-covalently with the crRNA and tracrRNA of the double gRNA, or by covalently or non-covalently linking the crRNA and tracrRNA.
- the linking domain may be homologous to or derived from a naturally occurring sequence, such as some sequences of tracrRNA.
- some or all of the base sequences of the linking domains may include chemical modifications.
- the chemical modification may be methylation, acetylation, phosphorylation, phosphorothioate linkage, locked nucleic acid (LNA), 2'-O-methyl 3'phosphorothioate (MS) or 2'-O-methyl 3'thioPACE (MSP). It is not limited.
- the second complementary domain comprises a complementary nucleic acid sequence with the first complementary domain and is complementary enough to form a double strand with the first complementary domain.
- the second complementary domain includes a complementary base sequence with the first complementary domain and a base sequence without complementarity with the first complementary domain, eg, a base sequence that does not form a double strand with the first complementary domain.
- the base sequence may be longer than the first complementary domain.
- the second complementary domain may be 5 to 35 base sequences.
- the first complementary domain may include 5 to 35 base sequences.
- the second complementary domain is 5 base sequence, 6 base sequence, 7 base sequence, 8 base sequence, 9 base sequence, 10 base sequence, 11 base sequence, 12 base Sequence, 13 bases, 14 bases, 15 bases, 16 bases, 17 bases, 18 bases, 19 bases, 20 bases, 21 bases, 22 bases Sequence, 23 nucleotide sequences, 24 nucleotide sequences, or 25 nucleotide sequences.
- the second complementary domain includes 5 base sequences, 6 base sequences, 7 base sequences, 8 base sequences, 9 base sequences, 10 base sequences, 11 base sequences, and 12 base sequences.
- the second complementary domain may have homology with a naturally occurring second complementary domain or may be derived from a naturally occurring second complementary domain.
- the second complementary domain may have a difference in the nucleotide sequence of the second complementary domain according to a species present in nature, may be derived from a second complementary domain including a species present in nature, or It may have some or complete homology with the second complementary domain, including species present in nature.
- the second complementary domain is Streptococcus pyogenes, Campylobacter jejuni, Streptococcus thermophilus, Streptococcus aureus ) Or a second complementary domain or derived second complementary domain of Neisseria meningitides, at least 50% or at least fully homologous.
- the second complementary domain is a second complementary domain of Streptococcus pyogenes or a second complementary domain derived from Streptococcus pyogenes
- the second complementary domain is 5′- UAGC AAGU UAAAA.
- U-3 ', or 5'- UAGC AAGU UAAAA U-3' may be a sequence having at least 50% homology with at least 50% (underlined marks to form a double strand with the first complementary domain) Sequence).
- the second complementary domain may further include (X) n or / and (X) m, that is, 5 ′-(X) n UAGC AAGU UAAAA U (X) m-3 ′.
- the X may be selected from the group consisting of bases A, T, U and G, wherein n and m are the number of base sequences, n may be an integer of 1 to 15, and m may be 1 to 6 have.
- (X) n may be repeated as many as n integers of the same base sequence, or may be an integer number of n base sequences in which bases A, T, U and G are mixed.
- (X) m may be repeated as many as m integers of the same base sequence, or may be m integer sequences of base A, T, U and G mixed.
- the second complementary domain when the first complementary domain is a second complementary domain of Campylobacter jejuni or a second complementary domain derived from Campylobacter jejuni, the second complementary domain is 5′- AAGAAAUUUAAAAAGGGACUAAAAU -3 'or 5'- AAGAAAUUUAAAAAGGGACUAAAAU -3' and may be a base sequence having at least 50% homology with at least 50% (underlined sequences to form a double strand with the first complementary domain).
- the second complementary domain may further comprise (X) n or / and (X) m, ie 5 ′-(X) n AAGAAAUUUAAAAAGGGACUAAAAU (X) m ⁇ 3 ′.
- X may be selected from the group consisting of bases A, T, U and G, n may be an integer of 1 to 15, and m may be 1 to 6.
- (X) n may be repeated as many as n integers of the same base sequence, or may be an integer number of n base sequences in which bases A, T, U and G are mixed.
- (X) m may be repeated as many as m integers of the same base sequence, or may be m integer sequences of base A, T, U and G mixed.
- the first complementary domain is Parcubacteria bacterium (GWC2011_GWC2_44_17), Lachnospiraceae bacterium (MC2017), Butyrivibrio proteoclascus (Butyrivibcus proteoclas , Peregrinibacteria bacterium (GW2011_GWA_33_10), Acidaminococcus sp. ), Porphyromonas crevioricanis, Prevotella disiens, Moraxella bovoculi (237), Smiihella sp.
- the second complementary domain when the second complementary domain is a second complementary domain of a Falcobacteria bacterium or a second complementary domain derived from Falcubacteria bacterium, the second complementary domain is 5′-AAAUU UCUAC U-3 Or a base sequence having at least 50% homology with at least 50% homology with 5′-AAAUU UCUAC U-3 ′ (an underlined sequence forms a double strand with the first complementary domain).
- the second complementary domain may further include (X) n or / and (X) m, that is, 5 ′-(X) n AAAUU UCUAC U (X) m ⁇ 3 ′.
- the X may be selected from the group consisting of bases A, T, U and G, wherein n and m are the number of base sequences, n may be an integer of 1 to 10, and m may be 1 to 6 have.
- (X) n may be repeated as many as n integers of the same base sequence, or may be an integer number of n base sequences in which bases A, T, U and G are mixed.
- (X) m may be repeated as many as m integers of the same base sequence, or may be m integer sequences of base A, T, U and G mixed.
- some or all of the base sequences of the second complementary domain may comprise chemical modifications.
- the chemical modification may be methylation, acetylation, phosphorylation, phosphorothioate linkage, locked nucleic acid (LNA), 2'-O-methyl 3'phosphorothioate (MS) or 2'-O-methyl 3'thioPACE (MSP). It is not limited.
- the proximal domain is one to twenty nucleotide sequences located close to the second complementary domain and is located in the 3 ′ direction of the second complementary domain. In this case, the proximal domain may form a double-stranded bond between complementary nucleotide sequences in the proximal domain.
- the proximal domain is 5 bases, 6 bases, 7 bases, 8 bases, 8 bases, 9 bases, 10 bases, 11 bases, 12 It can be a base sequence, 13 base sequences 14 base sequences or 15 base sequences.
- the proximal domain is 5 nucleotide sequences, 6 nucleotide sequences, 7 nucleotide sequences, 8 nucleotide sequences, 8 nucleotide sequences, 9 nucleotide sequences, 10 nucleotide sequences, 11 nucleotide sequences, 12 It may include the base sequence, 13 base sequences 14 base sequences or 15 base sequences.
- proximal domain may have homology with a naturally occurring proximal domain or may be derived from a naturally occurring proximal domain.
- proximal domain may have a difference in the nucleotide sequence of the proximal domain according to the species present in nature, may be derived from the proximal domain including the species present in nature, or the proximal domain including the species present in nature It may have some or complete homology with.
- the proximal domain is Streptococcus pyogenes, Campylobacter jejuni, Streptococcus thermophilus, Streptococcus aureus or Nay. Have at least 50%, or complete homology, with some or at least 50% of the proximal domain or the derived proximal domain of Neisseria meningitides.
- the proximal domain when the proximal domain is a proximal domain of Streptococcus pyogenes or a proximal domain derived from Streptococcus pyogenes, the proximal domain may be 5'-AAGGCUAGUCCG-3 ', or 5'-AAGGCUAGUCCG-3 'And some, at least 50% homology may be a base sequence.
- the proximal domain may further include (X) n, that is, 5′-AAGGCUAGUCCG (X) n-3 ′.
- X may be selected from the group consisting of bases A, T, U, and G, and n may be an integer of 1 to 15 as the number of base sequences.
- (X) n may be repeated as many as n integers of the same base sequence, or may be an integer number of n base sequences in which bases A, T, U and G are mixed.
- the proximal domain may be 5'-AAAGAGUUUGC-3 ', or 5'-AAAGAGUUUGC And a base sequence having at least 50% homology with -3 '.
- the proximal domain may further include (X) n, that is, 5′-AAAGAGUUUGC (X) n-3 ′.
- X may be selected from the group consisting of bases A, T, U and G, and n may be an integer of 1 to 40 as the number of base sequences.
- (X) n may be repeated as many as n integers of the same base sequence, or may be an integer number of n base sequences in which bases A, T, U and G are mixed.
- some or all of the base sequences of the proximal domain may comprise chemical modifications.
- the chemical modification may be methylation, acetylation, phosphorylation, phosphorothioate linkage, locked nucleic acid (LNA), 2'-O-methyl 3'phosphorothioate (MS) or 2'-O-methyl 3'thioPACE (MSP). It is not limited.
- the tail domain is a domain that can be optionally added to the 3 'end of a single stranded or double gRNA, the tail domain can be from 1 to 50 nucleotide sequences, or the tail domain can comprise from 1 to 50 nucleotide sequences. can do. In this case, the tail domain may form a double-stranded bond between complementary nucleotide sequences in the tail domain.
- the tail domain is 1 to 5 base sequences, 5 to 10 base sequences, 10 to 15 base sequences, 15 to 20 base sequences, 20 to 25 base sequences, 25 to 30 base sequences , 30 to 35 base sequences, 35 to 40 base sequences, 40 to 45 base sequences or 45 to 50 base sequences can be.
- the tail domain has 1 to 5 base sequences, 5 to 10 base sequences, 10 to 15 base sequences, 15 to 20 base sequences, 20 to 25 base sequences, and 25 to 30 base sequences. , 30 to 35 base sequences, 35 to 40 base sequences, 40 to 45 base sequences or 45 to 50 base sequences may be included.
- the tail domain may have homology with a naturally occurring tail domain or may be derived from a naturally occurring tail domain.
- the tail domain may have a difference in the nucleotide sequence of the tail domain according to the species present in nature, may be derived from the tail domain including the species present in nature, or the tail domain including the species present in nature It may have some or complete homology with.
- the tail domain is Streptococcus pyogenes, Campylobacter jejuni, Streptococcus thermophilus, Streptococcus aureus or Ney It may have at least 50%, or complete homology, with at least 50% of the tail or derived tail domains of Neisseria meningitides.
- the tail domain may be 5'-UUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC-3 ', or 5'-UUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC-3 'And some, at least 50% homology may be a base sequence.
- the tail domain may further include (X) n, that is, 5′-UUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (X) n-3 ′.
- X may be selected from the group consisting of bases A, T, U, and G, and n may be an integer of 1 to 15 as the number of base sequences. In this case, (X) n may be repeated as many as n integers of the same base sequence, or may be an integer number of n base sequences in which bases A, T, U and G are mixed.
- the tail domain is a Campylobacter jejuni's tail domain or a Campylobacter jejuni derived tail domain
- the tail domain can be 5'-GGGACUCUGCGGGGUUACAAUCCCCUAAAACCGCUUUU-3 ', or 5'-GGGACUCUGCGGGGUUACAAUCCCCUAUAACCG And a base sequence having at least 50% homology with -3 '.
- the tail domain may further include (X) n, that is, 5′-GGGACUCUGCGGGGUUACAAUCCCCUAAAACCGCUUUU (X) n-3 ′.
- X may be selected from the group consisting of bases A, T, U, and G, and n may be an integer of 1 to 15 as the number of base sequences. In this case, (X) n may be repeated as many as n integers of the same base sequence, or may be an integer number of n base sequences in which bases A, T, U and G are mixed.
- the tail domain may comprise 1 to 10 nucleotide sequences at the 3 ′ end associated with in vitro or in vivo transcription methods.
- the tail domain can be any nucleotide sequence present at the 3 ′ end of the DNA template.
- the tail domain may be UUUUUU
- the tail domain may be UUUU
- the pol-III promoter may comprise several uracil bases or alternative bases.
- part or all of the nucleotide sequence of the tail domain may comprise a chemical modification.
- the chemical modification may be methylation, acetylation, phosphorylation, phosphorothioate linkage, locked nucleic acid (LNA), 2'-O-methyl 3'phosphorothioate (MS) or 2'-O-methyl 3'thioPACE (MSP). It is not limited.
- the gRNA may comprise a plurality of domains as described above, allowing the length of the nucleic acid sequence to be adjusted depending on the domain that the gRNA contains, with each domain within or stranding the three-dimensional behavior or active form of the gRNA Can interact with each other.
- gRNAs include single-stranded gRNAs (single RNA molecules); Or double gRNA (comprising more than one typically two separate RNA molecules).
- Double gRNAs consist of a first strand and a second strand.
- the first strand may be referred to as crRNA
- the second strand may be referred to as tracrRNA.
- the guide domain comprises a complementary guide sequence capable of complementary binding to the target sequence on the target gene or nucleic acid.
- the guide sequence is a nucleic acid sequence that is complementary to the target sequence on the target gene or nucleic acid, for example at least 70%, 75%, 80%, 85%, 90% or 95% or more complementary or completely complementary nucleic acid sequence. Can be.
- the guide domain is believed to play a role in specific interactions with the target gene or nucleic acid of the gRNA-Cas complex, ie the CRISPR complex.
- the guide domain may be 5 to 50 base sequences, or may include 5 to 50 base sequences.
- the guide domain may include 16 nucleotide sequences, 17 nucleotide sequences, 18 nucleotide sequences, 19 nucleotide sequences, 20 nucleotide sequences, 21 nucleotide sequences, 22 nucleotide sequences, 23 nucleotide sequences, and 24 nucleotide sequences. Or 25 sequences, or may include the same.
- the guide domain may comprise a guide sequence.
- the guide sequence may be a complementary nucleotide sequence or a base sequence having complementarity capable of complementary binding to the target sequence on the target gene or nucleic acid, for example at least 70%, 75%, 80%, 85% At least 90% or 95% complementary or completely complementary sequences.
- the guide sequence may be 5 to 50 base sequences, or may include 5 to 50 base sequences.
- the guide sequence is 16 bases, 17 bases, 18 bases, 19 bases, 20 bases, 21 bases, 22 bases, 23 bases, 24 bases It may be a base sequence or 25 base sequences, or may include the same.
- the guide domain may comprise a guide sequence and an additional base sequence.
- the additional base sequence may be 1 to 35 base sequences.
- the additional base sequence may include one nucleotide sequence, two nucleotide sequences, three nucleotide sequences, four nucleotide sequences, five nucleotide sequences, six nucleotide sequences, seven nucleotide sequences, eight nucleotide sequences, and 9 nucleotide sequences. It can be a base sequence or 10 base sequences.
- the additional base sequence may be one base sequence G (guanine), or may be two base sequences GG.
- the additional base sequence may be located at the 5 'end of the guide domain, or may be located at the 5' end of the guide sequence.
- the additional base sequence may be located at the 3 'end of the guide domain, or may be located at the 3' end of the guide sequence.
- the first complementary domain comprises a complementary nucleic acid sequence with the second complementary domain of the second strand, and is a domain having a complementary enough to form a double strand with the second complementary domain.
- the first complementary domain may be 5 to 35 nucleotide sequences, or may include 5 to 35 nucleotide sequences.
- the first complementary domain includes five nucleotide sequences, six nucleotide sequences, seven nucleotide sequences, eight nucleotide sequences, nine nucleotide sequences, ten nucleotide sequences, eleven nucleotide sequences, twelve nucleotide sequences, 13 nucleotide sequences, 14 nucleotide sequences, 15 nucleotide sequences, 16 nucleotide sequences, 17 nucleotide sequences, 18 nucleotide sequences, 19 nucleotide sequences, 20 nucleotide sequences, 21 nucleotide sequences, 22 nucleotide sequences, It may be 23 base sequences, 24 base sequences, or 25 base sequences, or may include the same.
- the first complementary domain may have homology with a naturally occurring first complementary domain or may be derived from a naturally occurring first complementary domain.
- the first complementary domain may have a difference in the nucleotide sequence of the first complementary domain according to a species present in nature, may be derived from a first complementary domain including a species present in nature, or It may have some or complete homology with the first complementary domain comprising the species present in nature.
- the first complementary domain is Streptococcus pyogenes , Campylobacter jejuni ), Streptococcus thermophilus ), Streptococcus aureus , or Neisseria meningiditis meningitides ), at least 50%, or completely homologous with the first complementary domain or the derived first complementary domain.
- the first complementary domain may comprise additional sequences that do not complementarily bind to the second complementary domain of the second strand.
- the additional base sequence may be 1 to 15 base sequences.
- the additional base sequence may be 1 to 5 base sequences, 5 to 10 base sequences, or 10 to 15 base sequences.
- some or all of the base sequences of the guide domain and / or the first complementary domain may comprise chemical modifications.
- the chemical modification may be methylation, acetylation, phosphorylation, phosphorothioate linkage, locked nucleic acid (LNA), 2'-O-methyl 3'phosphorothioate (MS) or 2'-O-methyl 3'thioPACE (MSP). It is not limited.
- the first strand may be composed of 5 '-[guide domain]-[first complementary domain] -3' as described above.
- first strand may optionally include additional nucleotide sequences.
- the first strand is
- the N target is a base sequence capable of complementary binding to the target sequence on the target gene or nucleic acid
- the N target is a base sequence region that can be changed according to the target sequence on the target gene or nucleic acid.
- (Q) m is a nucleotide sequence including the first complementary domain, and includes a base sequence capable of complementary binding to the second complementary domain of the second strand.
- the (Q) m may be a sequence having a part or complete homology with the first complementary domain of a species present in nature, and the base sequence of the first complementary domain may be changed according to the derived species.
- Q may be independently selected from the group consisting of A, U, C, and G, and m may be an integer of 5 to 35 as the number of base sequences.
- (Q) m May be 5'-GUUUUAGAGCUA-3 ', or may be a nucleotide sequence having at least 50% homology with 5'-GUUUUAGAGCUA-3'.
- (Q) m is 5'-GUUUUAGUCCCUUUUUAAAUUUCUU-3 'or a base sequence having at least 50% homology with 5'-GUUUUAGUCCCUUUUUAAAUUUCUU-3'.
- (Q) m May be 5'-GUUUUAGAGCUGUGUUGUUUCG-3 ', or may be a base sequence having at least 50% homology with 5'-GUUUUAGAGCUGUGUUGUUUCG-3'.
- (X) a , (X) b and (X) c is a nucleotide sequence that can be optionally added, wherein X may be independently selected from the group consisting of A, U, C and G, A, b, and c are the number of base sequences, and may be 0 or an integer of 1 to 20.
- the second strand consists of a second complementary domain and a proximal domain and may optionally further comprise a tail domain.
- the second complementary domain in the second strand comprises a complementary nucleic acid sequence with the first complementary domain of the first strand and is complementary enough to form a double strand with the first complementary domain.
- the second complementary domain includes a complementary base sequence with the first complementary domain and a base sequence without complementarity with the first complementary domain, eg, a base sequence that does not form a double strand with the first complementary domain.
- the base sequence may be longer than the first complementary domain.
- the second complementary domain may be 5 to 35 nucleotide sequences, or may include 5 to 35 nucleotide sequences.
- the second complementary domain includes 5 base sequences, 6 base sequences, 7 base sequences, 8 base sequences, 9 base sequences, 10 base sequences, 11 base sequences, and 12 base sequences.
- nucleotide sequences 13 nucleotide sequences, 14 nucleotide sequences, 15 nucleotide sequences, 16 nucleotide sequences, 17 nucleotide sequences, 18 nucleotide sequences, 19 nucleotide sequences, 20 nucleotide sequences, 21 nucleotide sequences, 22 nucleotide sequences , 23 base sequences, 24 base sequences or 25 base sequences, or may include the same.
- the second complementary domain may have homology with a naturally occurring second complementary domain or may be derived from a naturally occurring second complementary domain.
- the second complementary domain may have a difference in the nucleotide sequence of the second complementary domain according to a species present in nature, may be derived from a second complementary domain including a species present in nature, or It may have some or complete homology with the second complementary domain, including species present in nature.
- the second complementary domain is Streptococcus pyogenes , Campylobacter jejuni ), Streptococcus thermophilus ), Streptococcus aureus , or Neisseria meningiditis meningitides ) or at least 50%, or complete homology, with a second complementary domain or derived second complementary domain.
- the second complementary domain may comprise additional sequences that do not complementarily bind to the first complementary domain of the first strand.
- the additional base sequence may be 1 to 25 base sequences.
- the additional base sequence may be 1 to 5 base sequences, 5 to 10 base sequences, 10 to 15 base sequences, 15 to 20 base sequences, or 20 to 25 base sequences.
- the proximal domain in the second strand is 1-20 nucleotide sequences, which is located in the 3 'direction of the second complementary domain.
- the proximal domain includes five nucleotide sequences, six nucleotide sequences, seven nucleotide sequences, eight nucleotide sequences, eight nucleotide sequences, nine nucleotide sequences, ten nucleotide sequences, eleven nucleotide sequences, and twelve nucleotide sequences. It may be a nucleotide sequence, 13 base sequences, 14 base sequences or 15 base sequences, or may include the same.
- the proximal domain may form a double-stranded bond between complementary nucleotide sequences in the proximal domain.
- proximal domain may have homology with a naturally occurring proximal domain or may be derived from a naturally occurring proximal domain.
- proximal domain may have a difference in the nucleotide sequence of the proximal domain according to the species present in nature, may be derived from the proximal domain including the species present in nature, or the proximal domain including the species present in nature It may have some or complete homology with.
- the proximal domain is Streptococcus pyogenes , Campylobacter jejuni ), Streptococcus thermophilus ), Streptococcus aureus , or Neisseria meningiditis meningitides ) may have some, at least 50%, or complete homology with the proximal domain or derived proximal domain.
- the tail domain in the second strand is a domain that can be selectively added to the 3 'end of the second strand
- the tail domain can be 1 to 50 nucleotide sequences, or 1 to 50 nucleotide sequences It may include.
- the tail domain may include 1 to 5 base sequences, 5 to 10 base sequences, 10 to 15 base sequences, 15 to 20 base sequences, 20 to 25 base sequences, 25 to 30 base sequences, It may be 30 to 35 base sequences, 35 to 40 base sequences, 40 to 45 base sequences or 45 to 50 base sequences, or may include the same.
- the tail domain may form a double-stranded bond between complementary nucleotide sequences in the tail domain.
- the tail domain may have homology with a naturally occurring tail domain or may be derived from a naturally occurring tail domain.
- the tail domain may have a difference in the nucleotide sequence of the tail domain according to the species present in nature, may be derived from the tail domain including the species present in nature, or the tail domain including the species present in nature It may have some or complete homology with.
- the tail domain is Streptococcus pyogenes , Campylobacter jejuni ), Streptococcus thermophilus ), Streptococcus aureus , or Neisseria meningiditis meningitides ) or at least 50%, or complete homology with the tail domain or derived tail domain.
- the tail domain may comprise 1 to 10 nucleotide sequences at the 3 ′ end associated with in vitro or in vivo transcription methods.
- the tail domain can be any nucleotide sequence present at the 3 'end of the DNA template.
- the tail domain may be UUUUUU
- the tail domain may be UUUU
- the pol-III promoter may comprise several uracil bases or alternative bases.
- some or all of the base sequences of the second complementary domain, proximal domain, and / or tail domain may comprise chemical modifications.
- the chemical modification may be methylation, acetylation, phosphorylation, phosphorothioate linkage, locked nucleic acid (LNA), 2'-O-methyl 3'phosphorothioate (MS) or 2'-O-methyl 3'thioPACE (MSP). It is not limited.
- the second strand may be 5 '-[second complementary domain]-[proximal domain] -3' or 5 '-[second complementary domain]-[proximal domain]-[tail domain]-as described above. 3 '.
- the second strand may optionally include additional nucleotide sequences.
- the second strand is
- the second strand is
- (Z) h is a nucleotide sequence including the second complementary domain, and includes a base sequence capable of complementary binding to the first complementary domain of the first strand.
- (Z) h may be a sequence having partial or complete homology with a second complementary domain of a species present in nature, and the base sequence of the second complementary domain may be changed according to the derived species.
- Z may be independently selected from the group consisting of A, U, C, and G, and h may be an integer of 5 to 50 as the number of base sequences.
- (Z) h May be 5'-UAGCAAGUUAAAAU-3 ', or may be a base sequence having at least 50% homology with 5'-UAGCAAGUUAAAAU-3'.
- (Z) h is 5'-AAGAAAUUUAAAAAGGGACUAAAAU-3 'or may be a base sequence having at least 50% homology with 5'-AAGAAAUUUAAAAAGGGACUAAAAU-3'.
- (Z) h May be 5'-CGAAACAACACAGCGAGUUAAAAU-3 'or may be a base sequence having at least 50% homology with 5'-CGAAACAACACAGCGAGUUAAAAU-3'.
- (P) k is a nucleotide sequence including the proximal domain, and may be a sequence having partial or complete homology with the proximal domain of a species existing in nature, and the base sequence of the proximal domain is changed according to the derived species. Can be.
- the P may be independently selected from the group consisting of A, U, C and G, and k may be an integer of 1 to 20 as the number of base sequences.
- (P) k is 5'-AAGGCUAGUCCG-3 ' Or a base sequence having at least 50% homology with 5′-AAGGCUAGUCCG-3 ′.
- (P) k may be 5′-AAAGAGUUUGC-3 ′. Or a base sequence having at least 50% homology with 5′-AAAGAGUUUGC-3 ′.
- (P) k is 5′-AAGGCUUAGUCCG-3 ′
- a base sequence having at least 50% homology with 5′-AAGGCUUAGUCCG-3 ′ is 5′-AAGGCUUAGUCCG-3 ′.
- (F) i is a nucleotide sequence including a tail domain, and may be a sequence having partial or complete homology with a tail domain of a species existing in nature, and the nucleotide sequence of the tail domain is changed according to the derived species.
- F may be independently selected from the group consisting of A, U, C, and G, and i may be an integer of 1 to 50 as the number of base sequences.
- (F) i is 5'-UUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC-3 ' Or a base sequence having at least 50% homology with 5′-UUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC-3 ′.
- (F) i is 5′-GGGACUCUGCGGGGUUACAAUCCCCUAAAACCGCUUUU-3 ′ when the tail domain has part or complete homology with the tail domain of Campylobacter jejuni or the Campylobacter jejuni derived tail domain Or a base sequence having at least 50% homology with 5′-GGGACUCUGCGGGGUUACAAUCCCCUAAAACCGCUUUU-3 ′.
- tail domain has partial or complete homology with the tail domain of Streptococcus thermophilus or the Streptococcus thermophilus derived tail domain
- (F) i is 5′-UACUCAACUUGAAAAGGUGGCACCGAUUCGGUGUUUUU-3 '
- (F) i may include 1 to 10 nucleotide sequences at the 3 'end associated with in vitro or in vivo transcription methods.
- the tail domain can be any nucleotide sequence present at the 3 'end of the DNA template.
- the tail domain may be UUUUUU
- the tail domain may be UUUU
- the pol-III promoter may comprise several uracil bases or alternative bases.
- (X) d , (X) e and (X) f is a nucleotide sequence that can be optionally added, X may be independently selected from the group consisting of A, U, C and G, The d, e and f is the number of base sequences, it may be an integer of 0 or 1 to 20.
- Single-stranded gRNAs can be divided into two types.
- first and second strands of the double gRNA there is a single-stranded gRNA connecting the first and second strands of the double gRNA with a linking domain, wherein the single-stranded gRNA is 5 '-[first strand]-[linking domain]-[second strand ] -3 '.
- the single stranded gRNA is
- Each domain except the linking domain is identical to the description for each domain of the first and second strands of the double gRNA.
- the linking domain is a domain connecting the first strand and the second strand, specifically, a nucleic acid sequence capable of connecting the first and second complementary domains to generate a single-stranded gRNA. to be.
- the linking domain may be covalently or non-covalently coupled to the first complementary domain and the second complementary domain, or may be covalently or non-covalently linked to the first complementary domain and the second complementary domain.
- the linking domain may be 1 to 30 nucleotide sequences, or may include 1 to 30 nucleotide sequences.
- the linking domain may be 1 to 5 nucleotide sequences, 5 to 10 nucleotide sequences, 10 to 15 nucleotide sequences, 15 to 20 nucleotide sequences, 20 to 25 nucleotide sequences, or 25 to 30 nucleotide sequences. It may be, or may include it.
- the linking domain is suitable for use in single-stranded gRNA molecules and can be covalently or non-covalently linked to the first and second strands of a double gRNA, or covalently or non-covalently linked to the first and second strands.
- Single stranded gRNAs can be used to generate.
- the linking domain may be used to generate single-stranded gRNAs either covalently or non-covalently with the crRNA and tracrRNA of the double gRNA, or by covalently or non-covalently linking the crRNA and tracrRNA.
- the linking domain may be homologous to or derived from a naturally occurring sequence, such as some sequences of tracrRNA.
- some or all of the base sequences of the linking domains may include chemical modifications.
- the chemical modification may be methylation, acetylation, phosphorylation, phosphorothioate linkage, locked nucleic acid (LNA), 2'-O-methyl 3'phosphorothioate (MS) or 2'-O-methyl 3'thioPACE (MSP). It is not limited.
- single-stranded gRNAs are 5 '-[guide domain]-[first complementary domain]-[linking domain]-[second complementary domain]-[proximal domain] -3' as described above. Or 5 '-[guide domain]-[first complementary domain]-[connection domain]-[second complementary domain]-[proximal domain]-[tail domain] -3'. have.
- the single-stranded gRNA may optionally include additional nucleotide sequences.
- the single stranded gRNA is
- the single-stranded gRNA is
- the N target is a base sequence capable of complementary binding to the target sequence on the target gene or nucleic acid
- the N target is a base sequence region that can be changed according to the target sequence on the target gene or nucleic acid.
- (Q) m is a nucleotide sequence including the first complementary domain, and includes a base sequence capable of complementary binding to the second complementary domain.
- the (Q) m may be a sequence having a part or complete homology with the first complementary domain of a species present in nature, and the base sequence of the first complementary domain may be changed according to the derived species.
- Q may be independently selected from the group consisting of A, U, C, and G, and m may be an integer of 5 to 35 as the number of base sequences.
- (Q) m May be 5'-GUUUUAGAGCUA-3 ', or may be a nucleotide sequence having at least 50% homology with 5'-GUUUUAGAGCUA-3'.
- (Q) m is 5'-GUUUUAGUCCCUUUUUAAAUUUCUU-3 'or a base sequence having at least 50% homology with 5'-GUUUUAGUCCCUUUUUAAAUUUCUU-3'.
- (Q) m May be 5'-GUUUUAGAGCUGUGUUGUUUCG-3 ', or may be a base sequence having at least 50% homology with 5'-GUUUUAGAGCUGUGUUGUUUCG-3'.
- (L) j is a nucleotide sequence including a linking domain, which is a base sequence that can be produced by connecting the first complementary domain and the second complementary domain to generate a single stranded gRNA.
- L may be independently selected from the group consisting of A, U, C and G, wherein j is the number of base sequences, it may be an integer of 1 to 30.
- (Z) h is a nucleotide sequence including a second complementary domain, and includes a base sequence capable of complementary binding to the first complementary domain.
- (Z) h may be a sequence having partial or complete homology with a second complementary domain of a species present in nature, and the base sequence of the second complementary domain may be changed according to the derived species.
- Z may be independently selected from the group consisting of A, U, C, and G, and h may be an integer of 5 to 50 as the number of base sequences.
- (Z) h May be 5'-UAGCAAGUUAAAAU-3 ', or may be a base sequence having at least 50% homology with 5'-UAGCAAGUUAAAAU-3'.
- (Z) h is 5'-AAGAAAUUUAAAAAGGGACUAAAAU-3 'or may be a base sequence having at least 50% homology with 5'-AAGAAAUUUAAAAAGGGACUAAAAU-3'.
- (Z) h May be 5'-CGAAACAACACAGCGAGUUAAAAU-3 'or may be a base sequence having at least 50% homology with 5'-CGAAACAACACAGCGAGUUAAAAU-3'.
- (P) k is a nucleotide sequence including the proximal domain, and may be a sequence having partial or complete homology with the proximal domain of a species existing in nature, and the base sequence of the proximal domain is changed according to the derived species. Can be.
- the P may be independently selected from the group consisting of A, U, C and G, and k may be an integer of 1 to 20 as the number of base sequences.
- (P) k is 5'-AAGGCUAGUCCG-3 ' Or a base sequence having at least 50% homology with 5′-AAGGCUAGUCCG-3 ′.
- (P) k may be 5′-AAAGAGUUUGC-3 ′. Or a base sequence having at least 50% homology with 5′-AAAGAGUUUGC-3 ′.
- (P) k is 5′-AAGGCUUAGUCCG-3 ′
- a base sequence having at least 50% homology with 5′-AAGGCUUAGUCCG-3 ′ is 5′-AAGGCUUAGUCCG-3 ′.
- (F) i is a nucleotide sequence including a tail domain, and may be a sequence having partial or complete homology with a tail domain of a species existing in nature, and the nucleotide sequence of the tail domain is changed according to the derived species.
- F may be independently selected from the group consisting of A, U, C, and G, and i may be an integer of 1 to 50 as the number of base sequences.
- (F) i is 5'-UUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC-3 ' Or a base sequence having at least 50% homology with 5′-UUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC-3 ′.
- (F) i is 5′-GGGACUCUGCGGGGUUACAAUCCCCUAAAACCGCUUUU-3 ′ when the tail domain has part or complete homology with the tail domain of Campylobacter jejuni or the Campylobacter jejuni derived tail domain Or a base sequence having at least 50% homology with 5′-GGGACUCUGCGGGGUUACAAUCCCCUAAAACCGCUUUU-3 ′.
- tail domain has partial or complete homology with the tail domain of Streptococcus thermophilus or the Streptococcus thermophilus derived tail domain
- (F) i is 5′-UACUCAACUUGAAAAGGUGGCACCGAUUCGGUGUUUUU-3 '
- (F) i may include 1 to 10 nucleotide sequences at the 3 'end associated with in vitro or in vivo transcription methods.
- the tail domain can be any nucleotide sequence present at the 3 'end of the DNA template.
- the tail domain may be UUUUUU
- the tail domain may be UUUU
- the pol-III promoter may comprise several uracil bases or alternative bases.
- the (X) a , (X) b , (X) c , (X) d , (X) e and (X) f is a nucleotide sequence that can be optionally added, wherein X is A, U, It may be selected independently from the group consisting of C and G, wherein a, b, c, d, e and f is the number of base sequences, it may be an integer of 0 or 1 to 20.
- the single stranded gRNA may then be a single stranded gRNA consisting of a guide domain, a first complementary domain and a second complementary domain,
- the single-stranded gRNA is
- the guide domain comprises a complementary guide sequence capable of complementary binding to the target sequence on the target gene or nucleic acid.
- the guide sequence is a nucleic acid sequence that is complementary to the target sequence on the target gene or nucleic acid, for example at least 70%, 75%, 80%, 85%, 90% or 95% or more complementary or completely complementary nucleic acid sequence. Can be.
- the guide domain is believed to play a role in specific interactions with the target gene or nucleic acid of the gRNA-Cas complex, ie the CRISPR complex.
- the guide domain may be 5 to 50 base sequences, or may include 5 to 50 base sequences.
- the guide domain may include 16 nucleotide sequences, 17 nucleotide sequences, 18 nucleotide sequences, 19 nucleotide sequences, 20 nucleotide sequences, 21 nucleotide sequences, 22 nucleotide sequences, 23 nucleotide sequences, and 24 nucleotide sequences. Or 25 sequences, or may include the same.
- the guide domain may comprise a guide sequence.
- the guide sequence may be a complementary nucleotide sequence or a base sequence having complementarity capable of complementary binding to the target sequence on the target gene or nucleic acid, for example at least 70%, 75%, 80%, 85% At least 90% or 95% complementary or completely complementary sequences.
- the guide sequence may be 5 to 50 base sequences, or may include 5 to 50 base sequences.
- the guide sequence is 16 bases, 17 bases, 18 bases, 19 bases, 20 bases, 21 bases, 22 bases, 23 bases, 24 bases It may be a base sequence or 25 base sequences, or may include the same.
- the guide domain may comprise a guide sequence and an additional base sequence.
- the additional base sequence may be 1 to 35 base sequences.
- the additional base sequence may include one nucleotide sequence, two nucleotide sequences, three nucleotide sequences, four nucleotide sequences, five nucleotide sequences, six nucleotide sequences, seven nucleotide sequences, eight nucleotide sequences, and 9 nucleotide sequences. It can be a base sequence or 10 base sequences.
- the additional base sequence may be one base sequence G (guanine), or may be two base sequences GG.
- the additional base sequence may be located at the 5 'end of the guide domain, or may be located at the 5' end of the guide sequence.
- the additional base sequence may be located at the 3 'end of the guide domain, or may be located at the 3' end of the guide sequence.
- the first complementary domain includes a second complementary domain and a complementary nucleic acid sequence, and has a complementarity enough to form a double strand with the second complementary domain.
- the first complementary domain may be 5 to 35 nucleotide sequences, or may include 5 to 35 nucleotide sequences.
- the first complementary domain includes five nucleotide sequences, six nucleotide sequences, seven nucleotide sequences, eight nucleotide sequences, nine nucleotide sequences, ten nucleotide sequences, eleven nucleotide sequences, twelve nucleotide sequences, 13 nucleotide sequences, 14 nucleotide sequences, 15 nucleotide sequences, 16 nucleotide sequences, 17 nucleotide sequences, 18 nucleotide sequences, 19 nucleotide sequences, 20 nucleotide sequences, 21 nucleotide sequences, 22 nucleotide sequences, It may be 23 base sequences, 24 base sequences, or 25 base sequences, or may include the same.
- the first complementary domain may have homology with a naturally occurring first complementary domain or may be derived from a naturally occurring first complementary domain.
- the first complementary domain may have a difference in the nucleotide sequence of the first complementary domain according to a species present in nature, may be derived from a first complementary domain including a species present in nature, or It may have some or complete homology with the first complementary domain comprising the species present in nature.
- the first complementary domain palku bacterium tumefaciens (Parcubacteria bacterium (GWC2011_GWC2_44_17)), racheu furnace Spirra seae tumefaciens (Lachnospiraceae bacterium (MC2017)), butyronitrile Lee V. proteosome keulrasikeo switch (Butyrivibrio proteoclasiicus), Peregrinibacteria bacterium (GW2011_GWA_33_10), Acidaminococcus sp .
- BV3L6 Porphyromonas macacae , Laznopyraceae bacterium ( Lachnospiraceae) bacterium (ND2006)), Porphyromonas crevioricanis ), Prevotella disiens , Moraxella bovoculi (237)), Smiihella sp .
- the first complementary domain may comprise additional sequences that do not complementarily bind to the second complementary domain.
- the additional base sequence may be 1 to 15 base sequences.
- the additional base sequence may be 1 to 5 base sequences, 5 to 10 base sequences, or 10 to 15 base sequences.
- the second complementary domain comprises a complementary nucleic acid sequence with the first complementary domain of the first strand and has a complementarity enough to form a double strand with the first complementary domain.
- the second complementary domain includes a complementary base sequence with the first complementary domain and a base sequence without complementarity with the first complementary domain, eg, a base sequence that does not form a double strand with the first complementary domain.
- the base sequence may be longer than the first complementary domain.
- the second complementary domain may be 5 to 35 nucleotide sequences, or may include 5 to 35 nucleotide sequences.
- the second complementary domain includes 5 base sequences, 6 base sequences, 7 base sequences, 8 base sequences, 9 base sequences, 10 base sequences, 11 base sequences, and 12 base sequences.
- nucleotide sequences 13 nucleotide sequences, 14 nucleotide sequences, 15 nucleotide sequences, 16 nucleotide sequences, 17 nucleotide sequences, 18 nucleotide sequences, 19 nucleotide sequences, 20 nucleotide sequences, 21 nucleotide sequences, 22 nucleotide sequences , 23 base sequences, 24 base sequences or 25 base sequences, or may include the same.
- the second complementary domain may have homology with a naturally occurring second complementary domain or may be derived from a naturally occurring second complementary domain.
- the second complementary domain may have a difference in the nucleotide sequence of the second complementary domain according to a species present in nature, may be derived from a second complementary domain including a species present in nature, or It may have some or complete homology with the second complementary domain, including species present in nature.
- the second complementary domains palku bacterium tumefaciens (Parcubacteria bacterium (GWC2011_GWC2_44_17)), racheu furnace Spirra seae tumefaciens (Lachnospiraceae bacterium (MC2017)), butyronitrile Lee V. proteosome keulrasikeo switch (Butyrivibrio proteoclasiicus), Peregrinibacteria bacterium (GW2011_GWA_33_10), Acidaminococcus sp .
- BV3L6 Porphyromonas macacae , Laznopyraceae bacterium ( Lachnospiraceae) bacterium (ND2006)), Porphyromonas crevioricanis ), Prevotella disiens , Moraxella bovoculi (237)), Smiihella sp .
- the second complementary domain may comprise additional sequences that do not complementarily bind to the first complementary domain.
- the additional base sequence may be 1 to 15 base sequences.
- the additional base sequence may be 1 to 5 base sequences, 5 to 10 base sequences, or 10 to 15 base sequences.
- the linking domain is a nucleic acid sequence that allows the first and second complementary domains to be joined to produce a single stranded gRNA.
- the linking domain may be covalently or non-covalently coupled to the first complementary domain and the second complementary domain, or may be covalently or non-covalently linked to the first complementary domain and the second complementary domain.
- the linking domain may be 1 to 30 nucleotide sequences, or may include 1 to 30 nucleotide sequences.
- the linking domain may be 1 to 5 nucleotide sequences, 5 to 10 nucleotide sequences, 10 to 15 nucleotide sequences, 15 to 20 nucleotide sequences, 20 to 25 nucleotide sequences, or 25 to 30 nucleotide sequences. It may be, or may include it.
- some or all of the base sequences of the guide domain, the first complementary domain, the second complementary domain, and the linking domain may comprise chemical modifications.
- the chemical modification may be methylation, acetylation, phosphorylation, phosphorothioate linkage, locked nucleic acid (LNA), 2'-O-methyl 3'phosphorothioate (MS) or 2'-O-methyl 3'thioPACE (MSP). It is not limited.
- the single-stranded gRNA is 5 '-[second complementary domain]-[first complementary domain]-[guide domain] -3' or 5 '-[second complementary domain]-[ Linking domain]-[first complementary domain]-[guide domain] -3 '.
- the single-stranded gRNA may optionally include additional nucleotide sequences.
- the single stranded gRNA is
- the single-stranded gRNA is
Abstract
Description
Claims (34)
- 핵산서열 내 변형이 일어난, PD-1, CTLA-4, A20, Dgkα, Dgkζ, Fas, EGR2, PPP2R2D, PSGL-1, KDM6A 및 Tet2로 구성된 군에서 선택된 하나 이상의 인위적으로 조작된 면역조절 유전자.
- 제1항에 있어서,상기 핵산서열 내 변형은 가이드핵산-에디터단백질 복합체에 의해 인위적으로 일어난 것을 특징으로 하는, 인위적으로 조작된 면역조절 유전자.
- 제1항에 있어서,상기 면역 조절 유전자는 A20, Dgkα, Dgkζ, EGR2, PSGL-1 또는 KDM6A인 것을 특징으로 하는 인위적으로 조작된 면역조절 유전자.
- 제1항에 있어서,상기 유전자는 가이드핵산-에디터단백질 복합체에 의해 인위적으로 조작된 면역조절 유전자로서,상기 면역조절 유전자를 구성하는 핵산서열 내 PAM(proto-spacer-adjacent Motif) 서열 중 또는 이의 5' 말단 및/또는 3' 말단에 인접하여 위치하는 연속하는 1bp 내지 50bp의 염기 서열 부위 내의하나 이상의 뉴클레오타이드의 결실 또는 삽입;야생형 유전자와 상이한 하나 이상의 뉴클레오타이드로의 치환;외부 유래의 하나 이상의 뉴클레오타이드 삽입중 하나 이상의 핵산의 변형, 또는상기 면역조절 유전자를 구성하는 핵산서열 내 하나 이상의 뉴클레오타이드의 화학적 변형을 포함하는 것을 특징으로 하는 인위적으로 조작된 면역조절 유전자.
- 제1항에 있어서,상기 핵산의 변형은 유전자의 프로모터 영역에서 일어난 것을 특징으로 하는인위적으로 조작된 면역조절 유전자.
- 제1항에 있어서,상기 핵산의 변형은 유전자의 엑손 영역에서 일어난 것을 특징으로 하는 인위적으로 조작된 면역조절 유전자.
- 제1항에 있어서,상기 핵산의 변형은 유전자의 인트론 영역에서 일어난 것을 특징으로 하는 인위적으로 조작된 면역조절 유전자.
- 제1항에 있어서,상기 핵산의 변형은 유전자의 인핸서 영역에서 일어난 것을 특징으로 하는 인위적으로 조작된 면역조절 유전자.
- 제4항에 있어서,상기 PAM 서열은 하기의 서열 중 1 이상인 것을 특징으로 하는 인위적으로 조작된 면역조절 유전자(5'에서 3'방향으로 기재함).NGG(N은 A, T, C 또는 G임);NNNNRYAC(N은 각각 독립적으로 A, T, C 또는 G이고, R은 A또는 G이고, Y는 C 또는 T임);NNAGAAW(N은 각각 독립적으로 A, T, C 또는 G이고, W는 A 또는 T임);NNNNGATT(N은 각각 독립적으로 A, T, C 또는 G임);NNGRR(T)(N은 각각 독립적으로 A, T, C 또는 G이고, R은 A 또는 G이고, Y는 C 또는 T임); 및TTN(N은 A, T, C 또는 G임).
- PD-1, CTLA-4, A20, Dgkα, Dgkζ, Fas, EGR2, PPP2R2D, PSGL-1, KDM6A 및 Tet2 중 선택된 하나 이상의 유전자의 핵산 서열 중 서열번호 1 내지 289번의 타겟 서열에 각각 상보적인 결합을 형성할 수 있는 가이드 핵산
- 제10항에 있어서,이하의 군으로부터 선택되는 1이상의 가이드 핵산:A20 유전자 핵산 서열 중 서열번호 6 및 11의 타겟 서열에 각각 상보적인 결합을 형성할 수 있는 가이드 핵산;DGKa 유전자 핵산 서열 중 서열번호 19, 20, 21, 및 23의 타겟 서열에 각각 상보적인 결합을 형성할 수 있는 가이드 핵산;EGR2 유전자 핵산 서열 중 서열번호 25의 타겟 서열에 각각 상보적인 결합을 형성할 수 있는 가이드 핵산;PPP2R2D 유전자 핵산 서열 중 서열번호 64의 타겟 서열에 각각 상보적인 결합을 형성할 수 있는 가이드 핵산;PD-1 유전자 핵산 서열 중 서열번호 87 및 89의 타겟 서열에 각각 상보적인 결합을 형성할 수 있는 가이드 핵산;Dgkζ 유전자 핵산 서열 중 서열번호 109, 110, 111, 112 및 113의 타겟 서열에 각각 상보적인 결합을 형성할 수 있는 가이드 핵산;Tet-2 유전자 핵산 서열 중 서열번호 126, 128 및 129의 타겟 서열에 각각 상보적인 결합을 형성할 수 있는 가이드 핵산;PSGL-1 유전자 핵산 서열 중 서열번호 182의 타겟 서열에 각각 상보적인 결합을 형성할 수 있는 가이드 핵산;FAS 유전자 핵산 서열 중 서열번호 252, 254, 257 및 264의 타겟 서열에 각각 상보적인 결합을 형성할 수 있는 가이드 핵산; 및KDM6A 유전자 핵산 서열 중 서열번호 285의 타겟 서열에 각각 상보적인 결합을 형성할 수 있는 가이드 핵산.
- 제10항에 있어서,상기 가이드 핵산은 18 내지 23 bp의 뉴클레오타이드인, gRNA 분자.
- 핵산서열 내 변형이 일어난, PD-1, CTLA-4, A20, Dgkα, Dgkζ, Fas, EGR2, PPP2R2D, PSGL-1, KDM6A 및 Tet2로 구성된 군에서 선택된 하나 이상의 인위적으로 조작된 면역조절 유전자 및 이로부터 발현되는 산물 중 1이상을 포함하는, 인위적으로 조작된 면역세포.
- 제13항에 있어서,상기 면역세포는 T 세포, CAR-T 세포, NK 세포 및 NKT 세포로 구성된 군에서 선택된 1 이상의 세포인 것을 특징으로 하는 인위적으로 조작된 면역세포.
- 제13항에 있어서,상기 면역세포는 상기 면역조절 유전자의 활성이 억제 또는 불활성화되도록 인위적으로 조작된 면역세포
- 제13항에 있어서,상기 면역 세포는 키메라 항원 수용체(CAR)를 추가로 더 포함하고 있는 것을 특징으로 하는, 인위적으로 조작된 면역세포
- 제14항에 있어서,상기 T 세포는 키메라 항원 수용체(CAR) 또는 조작된 TCR(T-세포 수용체)를 추가로 더 포함하고 있는 것을 특징으로 하는, 인위적으로 조작된 면역세포
- 제13항에 있어서,상기 면역세포는 가이드핵산-에디터단백질 복합체 또는 이들을 암호화하는 핵산서열을 추가로 포함하는, 인위적으로 조작된 면역세포.
- 제18항에 있어서, 상기 에디터단백질은스트렙토코커스 피요게네스(Streptococcus pyogenes) 유래의 Cas9 단백질, 캄필로박터 제주니 (Campylobacter jejuni) 유래의 Cas9 단백질, 스트렙토코커스 써모필러스 (Streptococcus thermophilus) 유래의 Cas9 단백질, 스트렙토코커스 아우레우스 (Streptococcus aureus) 유래의 Cas9 단백질, 네이세리아 메닝기디티스 (Neisseria meningitidis)유래의 Cas9 단백질, 및 Cpf1 단백질로 이루어진 군에서 선택된 하나 이상인 것을 특징으로 하는 인위적으로 조작된 면역세포.
- 제18항에 있어서,상기 가이드 핵산은 PD-1, CTLA-4, A20, Dgkα, Dgkζ, Fas, EGR2, PPP2R2D, PSGL-1, KDM6A 및 Tet2 로 구성된 군에서 선택된 하나 이상의 유전자의 핵산 서열 중 서열번호 1 내지 289번의 타겟 서열에 각각 상보적인 결합을 형성할 수 있는 것을 특징으로 하는 인위적으로 조작된 면역세포.
- 제13항에 있어서,상기 면역세포는 핵산서열 내 변형이 일어난, 인위적으로 조작된 Dgkα 및 Dgkζ유전자 중 1 이상을 포함하고 있는 것을 특징으로 하는, 인위적으로 조작된 면역세포.
- 제13항에 있어서,상기 면역세포는 핵산서열 내 변형이 일어난, 인위적으로 조작된 Dgkα 및 Dgkζ유전자를 함께 포함하고 있는 것을 특징으로 하는, 인위적으로 조작된 면역세포.
- PD-1, CTLA-4, A20, Dgkα, Dgkζ, Fas, EGR2, PPP2R2D, PSGL-1, KDM6A 및 Tet2 로 구성된 군에서 선택된 하나 이상의 유전자의 핵산 서열 중 서열번호 1 내지 289번의 타겟 서열에 각각 상보적인 결합을 형성할 수 있는 가이드 핵산; 및에디터단백질 또는 이를 암호화하는 핵산을 포함하는 유전자 조작용 조성물
- 제23항에 있어서, 상기 에디터단백질은스트렙토코커스 피요게네스(Streptococcus pyogenes) 유래의 Cas9 단백질, 캄필로박터 제주니 (Campylobacter jejuni) 유래의 Cas9 단백질, 스트렙토코커스 써모필러스 (Streptococcus thermophilus) 유래의 Cas9 단백질, 스트렙토코커스 아우레우스 (Streptococcus aureus) 유래의 Cas9 단백질, 네이세리아 메닝기디티스 (Neisseria meningitidis)유래의 Cas9 단백질, 및 Cpf1 단백질로 이루어진 군에서 선택된 하나 이상인 것을 특징으로 하는 유전자 조작용 조성물
- 제23항에 있어서, 상기 유전자 조작은면역조절 유전자를 구성하는 핵산서열 내 PAM(proto-spacer-adjacent Motif) 서열 중 또는 이의 5' 말단 및/또는 3' 말단에 인접하여 위치하는 연속하는 1bp 내지 50bp의 염기 서열 부위 내의하나 이상의 뉴클레오타이드의 결실 또는 삽입;야생형 유전자와 상이한 하나 이상의 뉴클레오타이드로의 치환;외부 유래의 하나 이상의 뉴클레오타이드 삽입중 하나 이상의 핵산의 변형, 또는상기 면역조절 유전자를 구성하는 핵산서열 내 하나 이상의 뉴클레오타이드의 화학적 변형을 포함하는 것을 특징으로 하는 유전자 조작용 조성물
- 제24항에 있어서,상기 PAM 서열은 하기의 서열 중 1 이상인 것을 특징으로 하는 유전자 조작용 조성물(5'에서 3'방향으로 기재함):NGG(N은 A, T, C 또는 G임);NNNNRYAC(N은 각각 독립적으로 A, T, C 또는 G이고, R은 A또는 G이고, Y는 C 또는 T임);NNAGAAW(N은 각각 독립적으로 A, T, C 또는 G이고, W는 A 또는 T임);NNNNGATT(N은 각각 독립적으로 A, T, C 또는 G임);NNGRR(T)(N은 각각 독립적으로 A, T, C 또는 G이고, R은 A 또는 G이고, Y는 C 또는 T임); 및TTN(N은 A, T, C 또는 G임).
- 인체에서 분리된 면역세포에(a) PD-1, CTLA-4, A20, Dgkα, Dgkζ, Fas, EGR2, PPP2R2D, PSGL-1, KDM6A 및 Tet2 로 구성된 군에서 선택된 하나 이상의 유전자의 핵산 서열 중 서열번호 1 내지 289번의 타겟 서열에 각각 상보적인 결합을 형성할 수 있는 가이드 핵산; 및(b) 스트렙토코커스 피요게네스(Streptococcus pyogenes) 유래의 Cas9 단백질, 캄필로박터 제주니 (Campylobacter jejuni) 유래의 Cas9 단백질, 스트렙토코커스 써모필러스 (Streptococcus thermophilus) 유래의 Cas9 단백질, 스트렙토코커스 아우레우스 (Streptococcus aureus) 유래의 Cas9 단백질, 네이세리아 메닝기디티스 (Neisseria meningitidis)유래의 Cas9 단백질, 및 Cpf1 단백질로 이루어진 군에서 선택된 하나 이상인 에디터 단백질을접촉시키는 단계를 포함하는, 면역 세포를 인위적으로 조작하는 방법.
- 제27항에 있어서,상기 가이드 핵산 및 에디터 단백질은각각 핵산 서열의 형태로 1 이상의 벡터에 존재하거나, 또는가이드 핵산과 에디터 단백질의 결합으로 복합체를 형성하여 존재하는 것을 특징으로 하는 면역 세포를 인위적으로 조작하는 방법.
- 제27항에 있어서,상기 접촉시키는 단계는 생체 외에서 수행되는 것을 특징으로 하는 방법.
- 제27항에 있어서,상기 접촉시키는 단계는 전기천공법 (electroporation), 리포좀, 플라스미드, 바이러스 벡터, 나노파티클(nanoparticles) 및 PTD (Protein translocation domain) 융합 단백질 방법 중 선택되는 1이상의 방법으로 수행되는 것을 특징으로 하는 방법.
- 제30항에 있어서,상기 바이러스 벡터는 레트로바이러스, 렌티바이러스, 아데노바이러스, 아데노-연관 바이러스(AAV), 백시니아바이러스, 폭스바이러스 및 단순포진 바이러스로 구성된 군에서 선택되는 1이상인 것을 특징으로 하는 방법.
- PD-1, CTLA-4, A20, Dgkα, Dgkζ, Fas, EGR2, PPP2R2D, PSGL-1, KDM6A 및 Tet2 중 1 이상의 유전자를 서열분석함으로써 대상체에서 상기 면역 세포 표적 위치의 서열에 대한 정보를 제공하는 방법.
- 제32항의 방법을 통해 제공받은 정보를 이용하여 라이브러리를 구축하는 방법.
- (a) PD-1, CTLA-4, A20, Dgkα, Dgkζ, Fas, EGR2, PPP2R2D, PSGL-1, KDM6A 및 Tet2 로 구성된 군에서 선택된 하나 이상의 유전자의 핵산 서열 중 서열번호 1 내지 289번의 타겟 서열에 각각 상보적인 결합을 형성할 수 있는 가이드 핵산;(b) 스트렙토코커스 피요게네스(Streptococcus pyogenes) 유래의 Cas9 단백질, 캄필로박터 제주니 (Campylobacter jejuni) 유래의 Cas9 단백질, 스트렙토코커스 써모필러스 (Streptococcus thermophilus) 유래의 Cas9 단백질, 스트렙토코커스 아우레우스 (Streptococcus aureus) 유래의 Cas9 단백질, 네이세리아 메닝기디티스 (Neisseria meningitidis)유래의 Cas9 단백질, 및 Cpf1 단백질로 이루어진 군에서 선택된 하나 이상인 에디터 단백질 또는 이를 암호화하는 핵산을 포함하는 유전자 조작용 키트.
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112019002779-3A BR112019002779A2 (pt) | 2016-08-12 | 2017-08-14 | elemento imunorregulador manipulado e imunidade alterada por este |
CA3033736A CA3033736C (en) | 2016-08-12 | 2017-08-14 | Manipulated immunoregulatory element and immunity altered thereby |
EP17839891.3A EP3498846A4 (en) | 2016-08-12 | 2017-08-14 | MANIPULATED IMMUNEGULATORY ELEMENT AND CHANGED IMMUNITY |
US16/324,955 US20190185860A1 (en) | 2016-08-12 | 2017-08-14 | Manipulated Immunoregulatory Element And Immunity Altered Thereby |
CN201780063250.1A CN109844118A (zh) | 2016-08-12 | 2017-08-14 | 经操纵的免疫调节因子以及由此改变的免疫力 |
AU2017308473A AU2017308473B2 (en) | 2016-08-12 | 2017-08-14 | Manipulated immunoregulatory element and immunity altered thereby |
JP2019507817A JP7215808B2 (ja) | 2016-08-12 | 2017-08-14 | 操作された免疫調節エレメントおよび変更された免疫 |
RU2019106669A RU2767206C2 (ru) | 2016-08-12 | 2017-08-14 | Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента |
SG11201901184QA SG11201901184QA (en) | 2016-08-12 | 2017-08-14 | Manipulated immunoregulatory element and immunity altered thereby |
AU2018264636A AU2018264636B2 (en) | 2017-05-08 | 2018-05-08 | Artificially manipulated immune cell |
US16/611,383 US20210147798A1 (en) | 2017-05-08 | 2018-05-08 | Artificially Manipulated Immune Cell |
KR1020180052448A KR20180123445A (ko) | 2017-05-08 | 2018-05-08 | 인위적으로 조작된 조작면역세포 |
PCT/KR2018/005284 WO2018208067A1 (ko) | 2017-05-08 | 2018-05-08 | 인위적으로 조작된 조작면역세포 |
JP2019561310A JP7235391B2 (ja) | 2017-05-08 | 2018-05-08 | 人工的に操作された免疫細胞 |
CN201880045774.2A CN110914431B (zh) | 2017-05-08 | 2018-05-08 | 经人工操纵的免疫细胞 |
KR1020197036278A KR102338993B1 (ko) | 2017-05-08 | 2018-05-08 | 인위적으로 조작된 조작면역세포 |
JP2023004738A JP2023052426A (ja) | 2016-08-12 | 2023-01-16 | 操作された免疫調節エレメントおよび変更された免疫 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0103308 | 2016-08-12 | ||
KR1020160103308 | 2016-08-12 | ||
US201762502822P | 2017-05-08 | 2017-05-08 | |
US62/502,822 | 2017-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018030874A1 true WO2018030874A1 (ko) | 2018-02-15 |
Family
ID=61163220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/008835 WO2018030874A1 (ko) | 2016-08-12 | 2017-08-14 | 조작된 면역조절요소 및 이에 의해 변형된 면역 활성 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20180018457A (ko) |
WO (1) | WO2018030874A1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108753817A (zh) * | 2018-04-13 | 2018-11-06 | 北京华伟康信生物科技有限公司 | 增强细胞的抗癌能力的方法及采用该方法获得的增强型细胞 |
CN111321171A (zh) * | 2018-12-14 | 2020-06-23 | 江苏集萃药康生物科技有限公司 | 一种应用CRISPR/Cas9介导ES打靶技术制备基因打靶动物模型的方法 |
WO2020168392A1 (en) * | 2019-02-22 | 2020-08-27 | Garvan Institute Of Medical Research | Methods of modulating immune response via snvs of a20 that can "tune" the immune system of a subject |
WO2021044378A1 (en) * | 2019-09-06 | 2021-03-11 | Crispr Therapeutics Ag | Genetically engineered t cells having improved persistence in culture |
AU2018264636B2 (en) * | 2017-05-08 | 2022-03-17 | Toolgen Incorporated | Artificially manipulated immune cell |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220192163A1 (en) | 2019-03-26 | 2022-06-23 | Toolgen Incorporated | Hemophilia b rat model |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140120622A1 (en) * | 2012-10-10 | 2014-05-01 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
KR20150105635A (ko) * | 2012-12-12 | 2015-09-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
KR20160018425A (ko) * | 2014-08-06 | 2016-02-17 | 차의과학대학교 산학협력단 | 조직적합성항원 유전자들의 교정을 통하여 구축한, 면역적합형 세포 |
US20160120906A1 (en) * | 2013-05-13 | 2016-05-05 | Cellectis | Methods for engineering highly active t cell for immunotheraphy |
-
2017
- 2017-08-14 KR KR1020170103009A patent/KR20180018457A/ko active Search and Examination
- 2017-08-14 WO PCT/KR2017/008835 patent/WO2018030874A1/ko unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140120622A1 (en) * | 2012-10-10 | 2014-05-01 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
KR20150105635A (ko) * | 2012-12-12 | 2015-09-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
US20160120906A1 (en) * | 2013-05-13 | 2016-05-05 | Cellectis | Methods for engineering highly active t cell for immunotheraphy |
KR20160018425A (ko) * | 2014-08-06 | 2016-02-17 | 차의과학대학교 산학협력단 | 조직적합성항원 유전자들의 교정을 통하여 구축한, 면역적합형 세포 |
Non-Patent Citations (1)
Title |
---|
FAGERLUND, ROBERT D. ET AL.: "The Cpfl CRISPR-Cas Protein Expands Genome-editing Tools", GENOME BIOLOGY, vol. 16, 2015, pages 1 - 3, XP055271439 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018264636B2 (en) * | 2017-05-08 | 2022-03-17 | Toolgen Incorporated | Artificially manipulated immune cell |
CN108753817A (zh) * | 2018-04-13 | 2018-11-06 | 北京华伟康信生物科技有限公司 | 增强细胞的抗癌能力的方法及采用该方法获得的增强型细胞 |
CN111321171A (zh) * | 2018-12-14 | 2020-06-23 | 江苏集萃药康生物科技有限公司 | 一种应用CRISPR/Cas9介导ES打靶技术制备基因打靶动物模型的方法 |
WO2020168392A1 (en) * | 2019-02-22 | 2020-08-27 | Garvan Institute Of Medical Research | Methods of modulating immune response via snvs of a20 that can "tune" the immune system of a subject |
WO2021044378A1 (en) * | 2019-09-06 | 2021-03-11 | Crispr Therapeutics Ag | Genetically engineered t cells having improved persistence in culture |
US20210079347A1 (en) * | 2019-09-06 | 2021-03-18 | Crispr Therapeutics Ag | Genetically engineered t cells having improved persistence in culture |
Also Published As
Publication number | Publication date |
---|---|
KR20180018457A (ko) | 2018-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018030874A1 (ko) | 조작된 면역조절요소 및 이에 의해 변형된 면역 활성 | |
KR102276371B1 (ko) | 조작된 면역조절요소 및 이에 의해 변형된 면역 활성 | |
WO2018208067A1 (ko) | 인위적으로 조작된 조작면역세포 | |
AU2018220087B2 (en) | Hla g-modified cells and methods | |
AU2016231061B2 (en) | Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients | |
WO2018217064A2 (ko) | 형질전환된 t세포를 이용한 자연살해세포의 배양방법 | |
CN110869046A (zh) | 通用型抗cd22嵌合抗原受体工程化的免疫细胞 | |
WO2018088694A2 (ko) | 인위적으로 조작된 sc 기능 조절 시스템 | |
WO2020101361A1 (ko) | 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법 | |
CA2422597A1 (en) | T cell receptor transfer into a candidate effector cell or a precursor thereof | |
WO2018230976A1 (ko) | 반복 확장 돌연변이에 대한 게놈 편집 시스템 | |
WO2021170089A1 (en) | Engineering immune cells via simultaneous knock-in and gene disruption | |
WO2020085827A1 (ko) | 조작된 면역 세포 | |
WO2023167575A1 (ko) | 저면역원성 줄기세포, 줄기세포로부터 분화되거나 유래된 저면역원성 세포 및 이의 제조방법 | |
WO2023282730A1 (ko) | 트랜스포존 시스템 및 이의 용도 | |
WO2022010220A1 (ko) | 면역원성이 감소된 신규한 이식용 세포 | |
WO2022075784A1 (ko) | T 세포 수용체, t 세포 수용체를 포함하는 면역 세포 및 이를 이용하는 방법 | |
WO2024058589A1 (ko) | 유전자 가위 넉-인을 이용하여 제조한 키메릭 항원 수용체 세포 및 이의 용도 | |
WO2021145700A1 (ko) | 저산소 환경 하에서 높은 적응력을 가지는 세포 및 이의 용도 | |
WO2022220648A1 (ko) | Hla-dr 특이적 키메라 항원 수용체 및 이의 용도 | |
WO2023038475A1 (ko) | 유도 자연살해세포의 제조방법 및 그의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17839891 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3033736 Country of ref document: CA Ref document number: 2019507817 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017308473 Country of ref document: AU Date of ref document: 20170814 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017839891 Country of ref document: EP Effective date: 20190312 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019002779 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112019002779 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190211 |